СОПОЛИМЕРЫ ХИТОЗАНА И ПОЛИЭТИЛЕНГЛИКОЛЯ И ИСПОЛЬЗУЮЩИЕ ИХ СПОСОБЫ И УСТРОЙСТВА ДЛЯ ГЕРМЕТИЗАЦИИ ПОДВЕРГНУТЫХ ПУНКЦИИ КРОВЕНОСНЫХ СОСУДОВ

Настоящее изобретение относится к устройству для герметизации сквозных пункционных отверстий в ткани, а также к способу его выполнения. Устройство содержит герметизирующее средство, имеющее первую секцию, имеющую проксимальный конец, дистальный конец и первое поперечное сечение, и вторую секцию, имеющую второе поперечное сечение, продолжающуюся от дистального конца первой секции, и направляющий катетер, имеющий полость, в которой размещено герметизирующее средство. Диаметр устройства меньше, чем диаметр пункционного отверстия. Первая секция образована из лиофилизированного гидрогеля, содержащего хитозан, связанный с по меньшей мере одним полиэтиленгликолевым полимером. Указанный гидрогель расширяется при воздействии физиологической текучей среды в сквозном пункционном отверстии. Вторая секция содержит несшитые предшественники полиэтиленгликоля и не содержит хитозан. Настоящее изобретение обеспечивает повышение эффективности, например скорости и качества, герметизации пункционного отверстия ...

СРЕДСТВО ДЛЯ ДОСТАВКИ, ОБЕСПЕЧИВАЮЩЕЕ НЕПРЕРЫВНОЕИ/ИЛИ РЕГУЛИРУЕМОЕ ВЫСВОБОЖДЕНИЕ БИОЛОГИЧЕСКИ АКТИВНЫХ АГЕНТОВ

Изобретение относится к материалам, представляющим собой ксерогели двуокиси кремния (силикаксерогели) с регулируемой способностью к растворению, полученным в результате превращения золя в гель, и их применению. Средство для доставки включает медленно разлагаемую частицу ксерогеля диоксида кремния небольшого диаметра, полученного в процессе образования геля из золя, в котором гелеобразование золя и выпаривание воды или растворителя происходит одновременно, и биологически активный агент, отличный от ксерогеля диоксида кремния, включенный в структуру ксерогеля диоксида кремния путем добавления указанного биологически активного агента к реакционной смеси указанного процесса образования геля из золя на любой стадии указанного процесса. Изобретение позволяет получить ксерогель с регулируемой растворимостью 3 с. и 9 з.п.ф-лы, 1 ил., 6 табл.

СОПОЛИМЕРЫ ХИТОЗАНА И ПОЛИЭТИЛЕНГЛИКОЛЯ И ИСПОЛЬЗУЮЩИЕ ИХ СПОСОБЫ И УСТРОЙСТВА ДЛЯ ГЕРМЕТИЗАЦИИ ПОДВЕРГНУТЫХ ПУНКЦИИ КРОВЕНОСНЫХ СОСУДОВ

Настоящее изобретение относится к устройству для герметизации сквозных пункционных отверстий в ткани пациента, содержащему герметизирующее средство, имеющее первую секцию, выполненную из лиофилизированного гидрогеля, причем первая секция расширяется при воздействии на нее физиологической текучей среды внутри пункционного отверстия, при этом первая секция содержит гидрогель, содержащий хитозан, связанный с, по меньшей мере, одним полиэтиленгликолевым полимером, причем, при воздействии водной физиологической текучей среды, гидрогель расширяется и герметизирует сквозное пункционное отверстие в ткани, и направляющий катетер, имеющий полость, при этом герметизирующее средство размещено в полости направляющего катетера, при этом устройство имеет меньший диаметр, чем диаметр пункционного отверстия. Также заявлены способ герметизации пункционных отверстий, выполненных в сосуде, имеющих размер отверстия, составляющий 6 или более по французской шкале, с использованием устройства, имеющего меньший ...

АДГЕЗИВНАЯ КОМПОЗИЦИЯ

Изобретение относится к устройству для стомы, содержащее отверждаемую под воздействием влаги адгезивную композицию. Композиция содержит реакционно-способный компонент, который содержит реакционно-способный силиконовый полимер или смесь реакционно-способных силиконовых полимеров, компонент на основе клейкого материала, который содержит клеящийся при надавливании силиконовый клейкий материал или смесь клеящихся при надавливании силиконовых клейких материалов, представляющий собой поликонденсированную полиорганосилоксановую смолу, которая является продуктом или продуктами реакции полиорганосилоксана с концевыми силанольными группами и силикатной полиорганосилоксановой смолы, содержащей по меньшей мере одно силокси-звено SiO, или силсесквиоксан, имеющий формулу [RSiO], где каждый R отдельно представляет собой H, алкильную группу, арильную группу, реакционно-способную функциональную группу или алкоксигруппу, и n составляет от 4 до 18, в присутствии основания с получением поликонденсированной ...

БИОРАЗЛАГАЕМАЯ МЕДИЦИНСКАЯ КЛЕЯЩАЯ ИЛИ ГЕРМЕТИЗИРУЮЩАЯ КОМПОЗИЦИЯ

Изобретение относится к химико-фармацевтической промышленности и представляет собой медицинскую клеящую или заполняющую композицию для склеивания, заполнения, нанесения покрытия, образования раневого покрытия и гемостаза на биологических тканях, включающую: (a) первый компонент, содержащий окисленные гликозаминогликаны, получаемые окислением посредством введения формильной группы; и (b) второй компонент, содержащий полиамин, включающий две или более аминогруппы, причем рН второго компонента в водном растворе составляет от 8,5 до 11,0; в которой окисленный гликозаминогликан выбран из группы, состоящей из окисленной гиалуроновой кислоты, окисленного хондроитинсульфата, окисленного хондроитина, окисленного дерматансульфата и окисленного кератансульфата, и в которой полиамин выбран из группы, состоящей из полилизина, путресцина, кадаверина, спермидина, спермина, протамина и полиэтиленимина (ПЭИ). Изобретение позволяет создать клеящую или заполняющую композицию, пригодную для использования на ...

БИОРАЗЛАГАЕМЫЕ ЧАСТИЦЫ, МАТЕРИАЛ ДЛЯ ОККЛЮЗИИ СОСУДОВ И СПОСОБ ПОЛУЧЕНИЯ БИОРАЗЛАГАЕМЫХ ЧАСТИЦ

... 1. Биоразлагаемые частицы, содержащие синтетический полимер, химически сшитый с полиосновной карбоновой кислотой, причем указанные биоразлагаемые частицы имеют содержание воды от 20 до 90% в водонасыщенном состоянии.2. Биоразлагаемые частицы по п. 1, степень сжатия которых составляет 15-60% и коэффициент восстановления в водонасыщенном состоянии не ниже 15%.3. Биоразлагаемые частицы по п. 1 или 2, причем указанный синтетический полимер является: гомополимером или блок-сополимером водорастворимого полимера(ов), выбранного(ых) из группы, состоящей из полиэтиленгликоля, полипропиленгликоля, поливинилового спирта, полиакриловой кислоты, полигидроксиэтилакрилата, полигидроксиэтилметакрилата, поливинилпирролидона, карбоксиметилцеллюлозы, гидроксиметилцеллюлозы и гидроксиэтилцеллюлозы; или блок-сополимером указанного водорастворимого полимера или полимеров и мономера(ов), выбранного(ых) из группы, состоящей из α-гидроксикислот, циклических димеров α-гидроксикислот, гидроксидикарбоновых кислот ...

ПОЛИМЕРЫ, НЕПРОНИЦАЕМЫЕ ДЛЯ РЕНТГЕНОВСКОГО ИЗЛУЧЕНИЯ

УСТРОЙСТВО СБОРА ВЫДЕЛЕНИЙ ОРГАНИЗМА

... 1. Устройство сбора выделений организма, содержащее пакет сбора и клейкую прокладку для прикрепления к коже, при этом указанная прокладка содержит защитный слой, первый слой и второй слой гидроколлоидного клейкого вещества, где второй слой гидроколлоидного клейкого вещества, по меньшей мере, частично расположен между первым слоем гидроколлоидного клейкого вещества и защитным слоем, при этом первый и второй слои клейкого вещества состоят из непрерывной и прерывной фазы, в которомa) прерывная фаза первого слоя клейкого вещества содержит пектин, карбоксиметилцеллюлозу, желатин, гуаровую камедь и картофельный крахмал,b) прерывная фаза второго слоя клейкого вещества содержит карбоксиметилцеллюлозу, желатин и гуаровую камедь,c) состав непрерывной фазы первого слоя клейкого вещества содержит полиизобутилен, стирол блок-сополимер, бутилкаучук и реагент, придающий клейкость,d) состав непрерывной фазы второго слоя клейкого вещества содержит полиизобутилен и стирол блок-сополимер.2. Устройство сбора ...

УЛУЧШЕННОЕ УПЛОТНЕНИЕ МАНЖЕТЫ ДЛЯ ЭНДОТРАХЕАЛЬНЫХ ТРУБОК

... 1. Гелеобразующий уплотняющий материал для медицинского устройства, причем указанный гелеобразующий уплотняющий материал содержит: ! вязкоупругий материал, проявляющий первую вязкость при введении во внутреннюю полость; и ! вторую вязкость после нахождения во внутренней полости в течение заданного времени, причем указанная полость примыкает к медицинскому устройству, выполненному с возможностью перекрывать по меньшей мере участок указанной внутренней полости; ! при этом указанный вязкоупругий материал обеспечивает повышенную непроницаемость участка указанной внутренней полости, перекрытой медицинским устройством. ! 2. Гелеобразующий уплотняющий материал по п.1, в котором указанное медицинское устройство включает в себя надувную манжету. ! 3. Гелеобразующий уплотняющий материал по п.1, в котором гелеобразующий уплотняющий материал густеет и затем приклеивается к внутренним поверхностям указанной внутренней полости после нахождения во внутренней полости в течение заданного промежутка времени ...

Trockene hämostatische Zusammensetzungen und Verfahren zu ihrer Herstellung

Imageable polymers

Screen printing apparatus and method

A method of manufacturing a layer of a silicone material comprises delivering the silicone material from a reservoir 13, 14 to a dispensing nozzle 26 at a print head 16 whilst the silicone material is a liquid or flowable gel; dispensing the silicone material onto a template 28 having at least one aperture to allow the silicone material to pass through the template; depositing the silicone material from the aperture onto a substrate 11; and allowing the silicone material to cure on the substrate as a layer. The reservoir comprises a first reservoir 13 and a separate second reservoir 14, both the first and second reservoirs being connected to a mixing body 15 that is connected to the dispensing nozzle. The mixing body may be a static mixer such as an Archimedes type screw mixer. The substrate may be a polyurethane (PU) film provided on a paper carrier. The apparatus may include a flat bed dryer 18 and tower dryer 20. The apparatus may include different units of a process line including a ...

Stable wound care formulation

Disclosed is a gel formulation suitable for use in filling a wound cavity and delivering an active ingredient thereto, the gel further having a pH range of 4.5 to 8.5, low bioadhesive strength and cohesive integrity and being formed from a polymer having extensive hydroxyl functionalities, a cross-linker being a salt form of boron that produces borate ions in aqueous solution, at least one compound which has a beneficial effect asan active ingredient in the wound (e.g. lidocaine) and at least one modulator, the modulator being a low molecular weight species that is capable of binding borate or PVA in aqueous solution through a mono-diol or di-diol formation and reduces the pH of PVA-borate hydrogels; wherein the gel contains less than 5% acetic acid, has a degree of hydrolysis of between 95% and 100% and the polymer has a molecular weight of from 60,000 to 300,000 Daltons.

Skin compatible silicone composition

Screen printing apparatus and method

Non-stringy adhesive hydrophilic gels

DRY HÄMOSTATI COMPOSITIONS AND PROCEDURES FOR YOUR PRODUCTION

REDOX AND PHOTO INITIATOR SYSTEM FOR THE PRIMING OF IMPROVED ADHESION FROM GELS TO SUBSTRATES

SOLUBLE OXIDES FOR BIOLOGICAL APPLICATIONS

INTERPENETRIERENDE POLYMER NETWORKS FOR USE AS HIGH-STRENGTH ONE MEDICAL SEALANT

DEVICE FOR CATCHING BODY FLUIDS

DEVICE FOR CATCHING BODY FLUIDS

RAPIDLY EFFECT DRYING SEALING MATERIAL AS WELL AS PROCEDURE FOR THE USE AND PRODUCTION

BIOLOGICALLY COMPATIBLE ONE POLYMER DEVICE

NON--DEGRADABLE LITTLE POURING WATER-SOLUBLE ROENTGEN DENSITY OF HYDRAULIC GEL

BIOLOGICAL MATERIALS THE BY NUKLEOPHILE REACTION ARE ADDED ON CONJUGATED INSATIATED GROUPS

HYDRAULIC COLLOIDS ABSTENTION, DOUGHY COMPOSITION.

RELEASE CONTROLLED BIOLOGICAL DEGRADABLE ONES MULTIBLOKHYDROGENE AND YOUR USE SUCH AS CARRIER MATERIALS FUR PHARMAKOLOGISCH ACTIVEN OF WHO MATERIALS AND GEWEBEKONTAKTMATERIALEN

PRESSURE-SENSITIVE ADHESIVE COMPOSITION

LOCAL ADMINISTRATION OF FIBRINOLYSE STRENGTHENING MEANS

SEALING COMPOSITION FOR SURGICAL DRAINAGE OPENING

Cerebrospinal fluid leakage occlusion

Methods and materials for treating a cerebrospinal fluid leakage are described herein. One method for treating cerebrospinal fluid leakage includes occluding cerebrospinal fluid leakage by administering an effective amount of a self-assembling peptide solution to a target area of a cerebrospinal fluid leakage, where the self-assembling peptide is between 7 amino acids and 32 amino acids in length and the self-assembling peptide solution forms a hydrogel under physiological conditions.

METHODS FOR THE FORMATION OF HYDROGELS USING THIOSULFONATE COMPOSITIONS AND USES THEREOF

Biogel

A biogel, and kits, agents, and methods for formation of the biogel are described. The biogel can be used for a variety of applications, including haemostasis, wound sealing, tissue engineering or localised drug delivery.

Lung volume reduction therapy using crosslinked non-natural polymers

Tissue bulking and coating compositions

Dry hemostatic compositions and methods for their preparation

Means for controlled sealing of endovascular devices

Expandable sealing means for endoluminal devices have been developed for controlled activation. The devices have the benefits of a low profile mechanism (for both self-expanding and balloon-expanding prosthesis), contained, not open, release of the material, active conformation to the "leak sites" such that leakage areas are filled without disrupting the physical and functional integrity of the prosthesis, and on-demand, controlled activation, that may not be pressure activated.

Buffered adhesive compositions for skin-adhering products and methods of making same

Buffered adhesive compositions comprising a high molecular weight polymeric buffer and products such as wound dressings and ostomy skin barriers incorporating the compositions. Use of high molecular weight polymers that are rich in acidic sites. Polymers with polyacid unctionality can serve as buffers through the use of mixtures of their protonated and neutralized forms. A wound dressing that includes a flexible outer layer and a high molecular weight polymeric buffering adhesive applied to one side thereof, said adhesive providing pH buffering and fluid absorption with minimal irritation to a wearer's skin. An ostomy skin barrier that includes a high molecular weight polymeric buffering adhesive applied to one side thereof, said adhesive composition providing pH buffering and fluid absorption with minimal irritation to a wearer's skin.

Hemostatic composition

Tissue adhesives and sealants and method for their use

TISSUE ADHESIVES AND SEALANTS AND METHOD FOR THEIR Abstract Compositions provided by mixing a biotin-containing component and an avidin containing component are useful as an adhesive or sealant for medical/surgical uses.

Hydrogel implants with varying degrees of crosslinking

Hydrogel implants with varying degrees of crosslinking Abstract 5 The present disclosure relates to a hydrogel composition and methods of using the same. The hydrogel composition may include precursors that react with each other upon contact as well as precursors that react upon contact with an initiator. In embodiments, the resulting hydrogels may have varying levels of crosslinking with both denser and less dense regions.

Antiseptic polymer and synthesis thereof

According to the present invention there is provided a polymer comprising at least one antiseptic/analgesic/anti-inflammatory monomeric unit in conjunction with at least three further monomeric units, said three further monomeric units eliciting properties selected from the group consisting of: temperature activation, water solubility, mechanical strength, protein/polysaccharide bonding capacity, and combinations thereof. In particular, disclosed herein is a polymer, wherein: the water soluble monomeric unit is a hydrophilic ethylene glycol (OEGMA) moiety; the mechanical strength-conferring monomeric unit is polylactide-co-2-hydroxy ethylmethyl acrylate (PLA/HEMA); the protein-reactive monomeric unit is an N acryloxysuccinimide (NAS) moiety; and the thermosetting monomeric unit is an N isopropyl acrylamide (NIPAAm) moiety. The antiseptic/analgesic/anti-inflammatory monomeric unit comprises a methacrylic ester derivative of salicylic acid (5-HMA or 4-HMA, or a combination thereof).

TRIPLE NATURAL POLYMER VISCOELASTIC COMPOSITION

A triple natural polymer viscoelastic composition is disclosed. By combining glucosamine sulfate ("GS"), sodium hyaluronate ("HA") and chondroitin sulfate ("CS"), the triple natural polymer viscoelastic compositions of this invention can provide a viscoelastic agent at a surgical site that not only serves as a protective agent to ocular tissues, but that can also act as an agent to alleviate pain and inflammation associated with ocular surgery. Embodiments of this invention can comprise GS combined with existing HA/CS viscoelastic agents. Embodiments of this invention can also comprise GS and CS in combination with an irrigation solution. Further, to enhance retention time at the site of an intra-articulate application of an embodiment of this invention, the following biodegradable polymers may also be included in an embodiment of the compositions of the present invention: cellulose derivatives (e.g., hydroxypropylmethylcellulose, ethylcellulose, caboxymethylcellulose, etc.), carbopol, ...

METHOD AND MATERIAL FOR ENHANCE TISSUE-BIOMATERIAL INTEGRATION

The present invention provides a composition and method for the covalent binding of a hydrogel to an extracellular matrix (ECM). Therapeutic applications include tissue repair and delivery of drugs or cells.

CONTROLLED RELEASE OF ANTI-ARRHYTHMIC AGENTS FROM A BIODEGRADABLE POLYETHYLENE OXIDE HYDROGEL FOR LOCAL APPLICATION TO THE HEART

Methods for the simple, reliable application and local controlled release of selected anti-arrhythmia drugs from a hydrogel applied to or polymerized on the tissues of the heart or its vessels, especially in conjunction with cardiac bypass or other cardiac surgery, have been developed. The anti- arrhythmia drugs are incorporated into hydrogels that biodegrade and adhere to the tissues to which the anti-arrhythmic drugs are to be delivered. The hydrogels may be formed in vitro or in vivo. In a preferred embodiment, the drugs are effective to lengthen atrial effective refractory period. A particularly preferred drug is amiodarone.

CROSSLINKABLE MACROMERS

A crosslinkable macromer system and related methods of preparing the system and using the system in the form of a crosslinked matrix between a tissue site and an implant article such as a tissue implant or on the porous surface of a prosthetic device. The macromer system includes two or more polymer-pendent polymerizable groups and one or more initiator groups (e.g., polymer-pendent initiator groups). The polymerizable groups and the initiator group(s), when polymer-pendent, can be pendent on the same or different polymeric backbones. The macromer system provides advantages over the use of polymerizable macromers and separate, low molecular weight initiators, including advantages with respect to such properties as nontoxicity, efficiency, and solubility. A macromer system of the invention can be used as an interface between the tissue site and implant article in a manner sufficient to permit tissue growth through the corsslinked matrix and between the tissue site and implant. In a preferred ...

CROSSLINKABLE MACROMERS BEARING INITIATOR GROUPS

A crosslinkable macromer system that includes two or more polymer-pendent polymerizable groups and one or more polymer-pendent initiator groups. The polymerizable groups and the initiator group(s) can be pendent on the same or different polymeric backbones. The macromer system provides advantages over the use of polymerizable macromers and separate, low molecular weight initiators, including advantages with respect to such properties as nontoxicity, efficiency, and solubility.

HEAT ACTIVATED ADHESIVE COMPOSITION CONTAINING COCONUT OIL

The present invention relates to an adhesive composition applicable to skin comprising: (i) a polar oil or fat including (a) at least one triglyceride and/or (b) at least one fatty acid of the formula R-CO2H, wherein R is a C3 to C30 alkyl group; and (ii) at least one homopolymer, and/or copolymer. This invention also relates to a medical adhesive device including such adhesive composition.

BIODEGRADABLE POLYMERIC ENDOLUMINAL SEALING PROCESS, APPARATUS AND POLYMERIC PRODUCT FOR USE THEREIN

A novel process for paving or sealing the interior surface of a tissue lumen by entering the interior of the tissue lumen and applying a polymer to the interior surface of the tissue lumen. This is accomplished using a catheter which delivers the polymer to the tissue lumen and causes it to conform to the interior surface of lumen. The polymer can be delivered to the lumen as a monomer or prepolymer solution, or as an at least partially preformed layer on an expansile member.

BIODEGRADABLE POLYMERIC ENDOLUMINAL SEALING PROCESS, APPARATUS AND POLYMERIC PRODUCTS FOR USE THEREIN

A novel process for paving or sealing the interior surface of a tissue lumen by entering the interior of the tissue lumen and applying a polymer to the interior surface of the tissue lumen. This is accomplished using a catheter which delivers the polymer to the tissue lumen and causes it to conform to the interior surface of lumen. The polymer can be delivered to the lumen as a monomer or prepolymer solution, or as an at least partially preformed layer on an expansile member.

COMPOSITION FOR FILLING BONE DEFECTS

The invention is directed toward a formable bone composition for application to a bone defect site to promote new bone growth at the site which comprises a new bone growth inducing compound of demineralized lyophilized allograft bone particles: The particle size ranges from about 0.1 mm to about 1.0cm and is mixed in a hydrogel carrier containing a sodium phosphate saline buffer, the hydrogel component of the carrier ranging from about 1.0 to 5.0% of the composition and a pH between 6.8-7.4 with one or more additives of a cellular material, growth factor, demineralized bone chips or mineralized bone chips.

ADHESIVE PAD FOR OSTOMY USE

COMPOSITIONS AND METHODS FOR VAS-OCCLUSIVE CONTRACEPTION AND REVERSAL THEREOF

Disclosed are methods of delivering an agent to the lumen of the vas deferens under guidance of ultrasound imaging. The methods include vas-occlusive contraception in which the vas deferens is non-surgically isolated and an occlusive substance is percutaneously administered into the lumen of the vas deferens under ultrasound. Also disclosed are methods of reversal of vas-occlusive contraception and methods of delivering an agent to the lumen of the vas deferens. Also disclosed are compositions for use in the methods of the invention.

EMULSION COMPRISING PARTICLES

The present invention provides emulsion compositions comprising an continuous oil phase, a discontinuous aqueous phase and a plurality of microparticles. The composition may comprise a pharmaceutical active ingredient located in the oil phase, the particulate phase or the aqueous phase. The emulsion compositions have improved stability and coherence and are useful in the treatment of tumours by embolotherapy.

SPRAY-DRIED THROMBIN AND METHODS OF USING AND MAKING SPRAY-DRIED THROMBIN

Spray-dried thrombin materials obtained from feedstock solutions comprising less than 5% by weight albumin and excluding trehalose or other excipients as well as methods of manufacturing the thrombin materials and methods of treating bleeding wounds are disclosed. The methods of use include applying reconstituted spray-dried thrombin topically to a bleeding site, optionally in conjunction with gelatin.

CROSSLINKED GELS COMPRISING POLYALKYLENEIMINES, AND THEIR USES AS MEDICAL DEVICES

One aspect of the present invention generally relates to methods of sealing a wound or tissue plane or filling a void splace. In a preferred embodiment, the wound is an ophthalmic, pleural or dural wound. In certain instances, the compositions used to seal the wound or tissue plane comprises a polyalkyleneimine. In a prefered embodiment, the polyalkyleneimine is polyethyleneimine. Treatment of the polyethyleneimine with a cross- linking reagent causes the polyethyleneimine polymers to polymerize forming a seal. In certain instances, the cross-linking reagent is a polyethylene glycol having reactive terminal groups. In certain instances, the reactive terminal groups are activated esters, such as N-hydroxy succinimide ester. In certain instances, the reactive terminal groups are isocyanates. In certain instances, the polyethyleneimine has a lysine, cysteine, isocysteine or other nucleophilic group attached to the periphery of the polymer. In certain instances, the polyethyleneimine is mixed ...

ADHESIVE COMPOSITION AND FIXATION ELEMENT FOR HUMAN SKIN

L'invention a pour objet une composition adhésive destinée à assurer la fixation sur la peau humaine, comprenant une phase continue et une phase discontinue d'hydrocolloïdes, la phase continue comprenant en poids, sur la base du poids total de la composition adhésive : (i) 1 à 12% en poids d'un polymère séquencé de type styrène-isoprène-styrène ou styrène-butadiène-styrène, (i i) (a) 1 à 15% d'un polymère de type élastomère butyl, éventuellement en mélange avec jusqu'à 25% en poids de d'un polymère de type polyisobutylène, ou (b) plus de 10% à 30% d'un polymère de type polyisobutylène, exempt de polymère de type élastomère butyl, (iii) 1 à moins de 10% d'un polymère de type éthylène vinyl acétate, la somme de ces trois types de polymères représentant de 10 à 40%. 11 ...

NANOPARTICLES FOR USE IN BIOADHESION

Use of a composition of nanoparticles for gluing at least one hydrogel to at least one other article. Gel assemblies of good mechanical resistance can be obtained easily. Method for gluing at least one hydrogel to at least one other article, said method comprises: applying a composition of nanoparticles on at least one face of the hydrogel and applying the face of the hydrogel with the nanoparticles to the article.

NERVE REPAIR WITH A HYDROGEL AND OPTIONAL ADHESIVE

The subject invention provides materials and methods for effective nerve repair. In a preferred embodiment, the subject invention provides nerve repair methods comprising the use of a fibrin glue and a polyethylene glycol (PEG) hydrogel to coapt severed nerve stumps or nerve grafts.

HYDROGEL FILAMENTS FOR BIOMEDICAL USES

Described herein are apparatus, compositions, systems and associated methods to occlude structures and malformations with radiopaque hydrogel filaments with delayed controlled rates of expansion permitting the repositioning of the device once inside the structure or malformation. Further described is a device for implantation in an animal comprising a difunctional, low molecular weight ethylenically unsaturated shapeable macromer; an ethylenically unsaturated monomer; and a radiopaque element, wherein said device contains no support members. Methods of forming such devices are also disclosed.

NERVE REPAIR WITH A HYDROGEL AND OPTIONAL ADHESIVE

The subject invention provides materials and methods for effective nerve repair. In a preferred embodiment, the subject invention provides nerve repair methods comprising the use of a fibrin glue and a polyethylene glycol (PEG) hydrogel to coapt severed nerve stumps or nerve grafts.

SKIN CONTACT MATERIAL

A substrate based skin contact material formed from a hydrocolloid having a silicone based component extending over regions of the substrate surface. The adhesive is formed non- continuously over the substrate to provide areas devoid of adhesive to allow appreciable moisture transfer between the skin and substrate and improve the skin friendliness of the material during use and allow convenient removal with avoidance of skin irritation.

SKIN CONTACT MATERIAL

A substrate based skin contact material formed from a hydrocolloid having a silicone based component extending over regions of the substrate surface. The adhesive is formed non- continuously over the substrate to provide areas devoid of adhesive to allow appreciable moisture transfer between the skin and substrate and improve the skin friendliness of the material during use and allow convenient removal with avoidance of skin irritation.

BUFFERED ADHESIVE COMPOSITIONS FOR SKIN-ADHERING PRODUCTS AND METHODS OF MAKING SAME

Buffered adhesive compositions comprising a high molecular weight polymeric buffer and products such as wound dressings and ostomy skin barriers incorporating the compositions. Use of high molecular weight polymers that are rich in acidic sites. Polymers with polyacid unctionality can serve as buffers through the use of mixtures of their protonated and neutralized forms. A wound dressing that includes a flexible outer layer and a high molecular weight polymeric buffering adhesive applied to one side thereof, said adhesive providing pH buffering and fluid absorption with minimal irritation to a wearer's skin. An ostomy skin barrier that includes a high molecular weight polymeric buffering adhesive applied to one side thereof, said adhesive composition providing pH buffering and fluid absorption with minimal irritation to a wearer's skin.

BUFFERED ADHESIVE COMPOSITIONS FOR SKIN-ADHERING MEDICAL PRODUCTS

Provided are buffered adhesive compositions comprising a high molecular weight non-neutralized polymeric acid and a high molecular weight partially neutralized polymeric acid and products such as wound dressings and ostomy skin barriers incorporating the compositions.

HEMOSTATIC COMPOSITIONS

The invention discloses a hemostatic composition comprising: a) a biocompatible polymer in particulate form suitable for use in hemostasis, and b) one hydrophilic polymeric component comprising reactive groups.

VISCOUS HAEMOSTATIC COMPOSTIONS AND METHOD OF TREATMENT

A method of promoting haemostasis in a patient is provided by the administration, to the site of blood loss, of a viscous thixotropic haemostatic composition comprising an ionic precipitating agent, a fatty alcohol, an alcohol phosphate diester and one of an alkoxyether phosphate or a monoester phosphate of an alkoxylated fatty alcohol.

MALLEABLE PASTE FOR FILLING BONE DEFECTS

The invention is directed toward a malleable bone putty and a flowable gel composition for application to a bone defect site to promote new bone growth at the site which comprises a new bone growth inducing compound of demineralized lyophilized allograft bone powder. The bone powder has a particle size ranging from about 100 to about 850 microns and is mixed in a high molecular weight hydrogel carrier, the hydrogel component of the carrier ranging from about 0.3 to 3.0% of the composition and having a molecular weight of about at least 10,000 Daltons. The composition contains about 25% to about 4 0% bone powder and can be additionally provided with BMP's and a sodium phosphate buffer.

PROCEDURE FOR THE PRODUCTION OF A MASS FOR MEDICAL PURPOSES.

Adhesive composition

Hydrogel based on linear copolymer, and applications thereof

Imageable polymers

Gel dressing for wound healing

PASTE FOR THE PROTECTION OF THE SKIN

COMPOSITION PROTECTRICE DE SCELLEMENT, SOUS FORME MOULEE, POUR OUVERTURES DE DRAINAGE CHIRURGICAL

La présente invention concerne des compositions protectrices de scellement, se présentant sous la forme de feuilles ou anneaux moulés destinés à être appliqués autour d'ouvertures de drainage chirurgical d'un fluide. Ces compositions comprennent un mélange gélifié d'une gomme hydrocolloïdale particulaire absorbant l'eau et d'un polyalcool liquide non toxique et leur résistance à l'action du fluide drainé (par exemple l'urine ou les fluides intestinaux) est accrue, conformément à l'invention, par incorporation d'une petite quantité de silice colloïdale. On préfère utiliser la silice colloïdale préparée par voie sèche. En limitant la quantité de silice ajoutee, on peut éviter des réductions appréciables de l'adhésivité en milieu humide et/ou de l'adhésivité en milieu sec.

COMPOSITION FOR OSTOMIE

PHOSPHAZENE-BASED POLYMER FOR TISSUE ADHESION, PRODUCTION METHOD THEREOF, AND USE THEREOF

The present invention relates to a phosphazene-based polymer containing amino acid ester, polyethylene glycol, a group having a functional group for introducing a functional group at a terminal, and a catechol group bonded to a part or all of the functional groups directly or via a linker in a predetermined ratio. The present invention further relates to a production method thereof, and a composition for tissue adhesion containing the same as an active ingredient. COPYRIGHT KIPO 2018 (AA) Spilled blood volume (BB) Normal (CC) Example 1 (DD) Example 2 ...

폴리감마글루탐산 함유 하이드로겔 및 이를 포함하는 의료용 접착제 및 지혈제

... 본원은 폴리페놀 및 폴리감마글루탐산을 포함하는 하이드로겔, 이의 용도 및 이의 제조 방법에 관한 것이다.

composition, and, the kit

New Photoactive Bioadhesive Compositions

RAPIDLY ACTING DRY SEALANT AND METHODS FOR USE AND MANUFACTURE

Compositions, methods, and kits are provided for sealing applications. Compositions are prepared by combining a first cross-linkable component with a second cross linkable component to form a porous matrix having interstices, and combining the porous matrix with a hydrogel-forming component to fill at least some of the interstices. The compositions exhibit minimal swelling properties.

MULTIBLOCK BIODEGRADABLE HYDROGELS FOR USE AS CONTROLLED RELEASE AGENTS FOR DRUGS DELIVERY AND TISSUE TREATMENT AGENTS

Gel-forming macromers including at least four polymeric blocks, at least two of which are hydrophobic and at least one of which is hydrophilic, and including a cross-linkable group are provided. The macromers can be covalently cross-linked to form a gel on a tissue surface in vivo. The gels formed from the macromers have a combination of properties including thermosensitivity and lipophilicity, and are useful in a variety of medical applications including drug delivery and tissue coating.

METHODS OF BONDING OR MODIFYING HYDROGELS USING IRRADIATION

This invention provides methods and processes to attach or bond hydrogels to suitable surfaces using irradiation techniques and also provides methods and processes to create crosslinked regions in hydrogel articles using these irradiation techniques. Specifically, lasers at wavelengths tuned to the irradiation absorption bands of hydroxyl groups, carboxylic acid groups or water may be used to attach or bond hydrogels to surfaces such as soft tissue and hydrogel surfaces or to crosslink regions in hydrogel articles.

Photopolymerizable biodegradable hydrogels as tissue contacting materials and controlled-release carriers

Hydrogels of polymerized and crosslinked macromers comprising hydrophilic oligomers having biodegradable monomeric or oligomeric extensions, which biodegradable extensions are terminated on free ends with end cap monomers or oligomers capable of polymerization and cross linking are described. The hydrophilic core itself may be degradable, thus combining the core and extension functions. Macromers are polymerized using free radical initiators under the influence of long wavelength ultraviolet light, visible light excitation or thermal energy. Biodegradation occurs at the linkages within the extension oligomers and results in fragments which are non-toxic and easily removed from the body. Preferred applications for the hydrogels include prevention of adhesion formation after surgical procedures, controlled release of drugs and other bioactive species, temporary protection or separation of tissue surfaces, adhering of sealing tissues together, and preventing the attachment of cells to tissue ...

Fragmented polymeric compositions and methods for their use

Cross-linked hydrogels comprise a variety of biologic and non-biologic polymers, such as proteins, polysaccharides, and synthetic polymers. Such hydrogels preferably have no free aqueous phase and may be applied to target sites in a patient's body by extruding the hydrogel through an orifice at the target site. Alternatively, the hydrogels may be mechanically disrupted and used in implantable articles, such as breast implants. When used in vivo, the compositions are useful for controlled release drug delivery, for inhibiting post-surgical spinal and other tissue adhesions, for filling tissue divots, tissue tracts, body cavities, surgical defects, and the like.

Photo-crosslinked hydrogel material and preparation, composition, and application thereof photo-crosslinked hydrogel

This invention provides preparations, compositions, products, and applications of photo-crosslinked hydrogels. Component A—a photosensitive polymer derivative, component B—the photoinitiator, and auxiliary component C—other biocompatible polymer derivative each are respectively dissolved in a biocompatible medium to obtain solution A, solution B, and solution C. The solution A, the solution B, and the optional solution C are mixed homogenously to obtain a hydrogel precursor solution. The hydrogel precursor solution is subject to irradiation of the UV light for photocoupled crosslinking to form a photo-crosslinked hydrogel. The photo-crosslinked hydrogel exhibit rapid speed of photo-curing, strong tissue adhesion, excellent mechanical properties, good biocompatibility, and excellent clinical operability. In addition, this invention also provides a kit for making the photo-crosslinked hydrogel, and applications thereof in tissue engineering, regenerative medicine, 3D printing, and as a carrier ...

Methods of using in situ hydration of hydrogel articles for sealing or augmentation of tissue or vessels

Pharmaceutically acceptable hydrogel polymers of natural, recombinant or synthetic origin, or hybrids thereof, are introduced in a dry, less hydrated, or substantially deswollen state and rehydrate in a physiological environment to undergo a volumetric expansion and to affect sealing, plugging, or augmentation of tissue, defects in tissue, or of organs. The hydrogel polymers may deliver therapeutic entities by controlled release at the site. Methods to form useful devices from such polymers, and to implant the devices are provided.

Hydrogel implants with varying degrees of crosslinking

The present disclosure relates to a hydrogel composition and methods of using the same. The hydrogel composition may include precursors that react with each other upon contact as well as precursors that react upon contact with an initiator. In embodiments, the resulting hydrogels may have varying levels of crosslinking with both denser and less dense regions.

Drug Delivery from Embolic Agents

A pharmaceutical composition for embolisation of blood vessels, especially for benign tumours, comprises a polymeric embolic agent and, associated with the polymer in a releasable form, a local anaesthetic agent. The polymer is preferably in particulate form, such as in the form of microspheres. A suitable polymer is a crosslinked polyvinyl alcohol polymer formed by the copolymerisation of PVA macromer with other ethylenically unsaturated monomers. The composition provides a synergistic treatment for the symptoms of tumours such as uterine fibroids, leading to size regression as well as pain relief.

Injectable hydrogels

Described herein are methods of forming hydrogels comprising combining (a) a water-soluble polymer comprising thiol groups, and (b) a water-soluble metal salt in an aqueous solution. The hydrogels form rapidly. Hydrogels and related methods, uses, and products also are described.

HEMOSTATIC EFFICACY OF A NANOSTRUCTURED FIBRIN AGAROSE HYDROGEL

The present invention provides for nanostructured fibrin and agarose hydrogels, preferably type VII agarose hydrogels, (NFAH) or non-nanostructured or pre-nanostructured fibrin and agarose hydrogels, preferably type VII agarose hydrogels, (FAH), as hemostatic agents designed for use as an adjunct or primary treatment in moderate intraoperative hemorrhage and in trauma. These hydrogels can be applied topically to the wound either on the skin in a laparatomy or as non-invasive manner in surgical procedures. Its nanostructure technology generates an adhesive stable fibrin clot required for hemostasis. The attachment properties of the hydrogel, as well as the rapid formation of a fibrin clot, ensures that a strong stable fibrin clot is formed shortly after application. 1. A composition for use in the control of bleeding with or without compression , wherein the composition comprises nanostructured fibrin and agarose hydrogels , preferably type VII agarose hydrogels , (NFAH) or non-nanostructured or pre-nanostructured fibrin and agarose hydrogels , preferably type VII agarose hydrogels , (FAH).2. The composition for use in the control of bleeding according to claim 1 , wherein the composition is for use as biological tissue sealants and/or hemostats.3. The composition for use in the control of bleeding according to claim 1 , wherein the composition is for use as an adjunct to hemostasis in laparotomy or laparoscopic surgery claim 1 , in orthopedic surgery claim 1 , trauma (spleen laceration or hepatic surgery) claim 1 , or large-bed wounds.4. The composition for use in the control of bleeding according to claim 1 , wherein the composition is for use as adjunct and/or primary treatment in moderate bleeding.5. The composition for use according to any of to claim 1 , wherein the composition is cellularized nanostructured fibrin and agarose hydrogels claim 1 , preferably type VII agarose hydrogels claim 1 , (c-NFAH).6. The composition for use according to any of to claim 1 , ...

Меthоds оf using in situ hуdrаtiоn оf hуdrоgеl аrtiсlеs fоr sеаling оr аugmеntаtiоn оf tissuе оr vеssеls

Рhаrmасеutiсаllу ассеptаblе hуdrоgеl pоlуmеrs оf nаturаl, rесоmbinаnt оr sуnthеtiс оrigin, оr hуbrids thеrеоf, аrе intrоduсеd in а drу, lеss hуdrаtеd, оr substаntiаllу dеswоllеn stаtе аnd rеhуdrаtе in а phуsiоlоgiсаl еnvirоnmеnt tо undеrgо а vоlumеtriс ехpаnsiоn аnd tо аffесt sеаling, plugging, оr аugmеntаtiоn оf tissuе, dеfесts in tissuе, оr оf оrgаns. Тhе hуdrоgеl pоlуmеrs mау dеlivеr thеrаpеutiс еntitiеs bу соntrоllеd rеlеаsе аt thе sitе. Меthоds tо fоrm usеful dеviсеs frоm suсh pоlуmеrs, аnd tо implаnt thе dеviсеs аrе prоvidеd.

Меthоds оf using in situ hуdrаtiоn оf hуdrоgеl аrtiсlеs fоr sеаling оr аugmеntаtiоn оf tissuе оr vеssеls

Рhаrmасеutiсаllу ассеptаblе hуdrоgеl pоlуmеrs оf nаturаl, rесоmbinаnt оr sуnthеtiс оrigin, оr hуbrids thеrеоf, аrе intrоduсеd in а drу, lеss hуdrаtеd, оr substаntiаllу dеswоllеn stаtе аnd rеhуdrаtе in а phуsiоlоgiсаl еnvirоnmеnt tо undеrgо а vоlumеtriс ехpаnsiоn аnd tо аffесt sеаling, plugging, оr аugmеntаtiоn оf tissuе, dеfесts in tissuе, оr оf оrgаns. Тhе hуdrоgеl pоlуmеrs mау dеlivеr thеrаpеutiс еntitiеs bу соntrоllеd rеlеаsе аt thе sitе. Меthоds tо fоrm usеful dеviсеs frоm suсh pоlуmеrs, аnd tо implаnt thе dеviсеs аrе prоvidеd.

Меthоds оf using in situ hуdrаtiоn оf hуdrоgеl аrtiсlеs fоr sеаling оr аugmеntаtiоn оf tissuе оr vеssеls

Рhаrmасеutiсаllу ассеptаblе hуdrоgеl pоlуmеrs оf nаturаl, rесоmbinаnt оr sуnthеtiс оrigin, оr hуbrids thеrеоf, аrе intrоduсеd in а drу, lеss hуdrаtеd, оr substаntiаllу dеswоllеn stаtе аnd rеhуdrаtе in а phуsiоlоgiсаl еnvirоnmеnt tо undеrgо а vоlumеtriс ехpаnsiоn аnd tо аffесt sеаling, plugging, оr аugmеntаtiоn оf tissuе, dеfесts in tissuе, оr оf оrgаns. Тhе hуdrоgеl pоlуmеrs mау dеlivеr thеrаpеutiс еntitiеs bу соntrоllеd rеlеаsе аt thе sitе. Меthоds tо fоrm usеful dеviсеs frоm suсh pоlуmеrs, аnd tо implаnt thе dеviсеs аrе prоvidеd.

NOVEL GLUE FOR EMBOLIZATION OF LYMPHATIC LEAKAGE

A novel glue for embolization of lymphatic leakage. An optimized lymphatic embolization agent (LEA) as described herein comprises a NAM hydrogel and tantalum at a mixture of at or about 1:3 tantalum to NAM hydrogel, wherein said LEA is radiopaque.

THERMO-REVERSIBLE POLYMER FOR INTRALUMENAL IMPLANT

An intralumenal implant material, which comprises, a polymer having a sol-gel transition temperature in an aqueous solution thereof, shows a substantial water-insolubility at a temperature higher than the sol-gel transition temperature, and shows a thermo-reversible water-solubility at a temperature lower than the sol-gel transition temperature. Such an intralumenal implant is capable to be endovascularly or percutaneously delivered into a vascular lumen in a liquid state at the temperature lower than the sol-gel transition temperature, is capable to be instantly converted into a gel state in the vascular lumen at the blood temperature higher than the sol-gel transition temperature and is capable of occluding aneurysms, vascular tumors or vascular malformation. Such intralumenal implant material shows excellent biocompatibility and mechanical matching for the vascular tissue and the surrounding tissue because it is a highly water-containing hydrogel. In addition, biologically active substances ...

Hydrocolloid containing paste-like composition

Blood coagulation inducing polymer hydrogel

The present application is drawn to a synthetic, polymer hydrogel-based material, which is able to actively induce the body's natural hemostatic coagulation process in blood or acellular plasma. The present invention provides the development of a primary amine containing polymer hydrogel capable of inducing blood coagulation and delivering therapeutics for hemostatic or wound care applications, and a method of forming such a primary amine containing polymer hydrogel capable of inducing the blood coagulation process. The primary amine containing polymer hydrogel is able to achieve the same end result as biological-based hemostatics, without the innate risk of disease transmission or immunological response, and at a fraction of the price. Furthermore, due to its inherent hydrogel-based design the material has the capability of arresting blood loss while simultaneously delivering therapeutics in a controlled manner, potentially revolutionizing the way in which wounds are treated.

Reversible oral adhesive gel

The invention relates to a reversible oral adhesive gel. The reversible oral adhesive gel is suitable for application to lips to inhibit oral (mouth) breathing and to promote nasal breathing and thereby prevent or ameliorate snoring and to correct other respiratory problems.

Polysaccharide Based Hydrogels

Polysaccharide based hydrogel compositions and methods of making and using the same are provided. The subject polysaccharide based hydrogel compositions are prepared by combining a polysaccharide component with a hydrophilic polymer and a cross-linking agent. Also provided are kits and systems for use in preparing the subject compositions.

Peg based hydrogel for peripheral nerve injury applications and compositions and method of use of synthetic hydrogel sealants

Hydrogels that may be used for treating peripheral nerves and related methods are provided. Synthetic hydrogel sealants, methods of forming synthetic hydrogel sealants, and the use of synthetic hydrogel sealants are provided.

Temporary Embolization Using Inverse Thermosensitive Polymers

One aspect of the present invention relates to methods of embolizing a vascular site in a mammal comprising introducing into the vasculature of a mammal a composition comprising an inverse thermosensitive polymer, wherein said inverse thermosensitive polymer gels in said vasculature, which composition may be injected through a small catheter, and which compositions gel at or below body temperature. In certain embodiments of the methods of embolization, said composition further comprises a marker molecule, such as a dye, radiopaque, or an MRI-visible compound.

Lung Volume Reduction Therapy Using Crosslinked Non-Natural Polymers

One aspect of the invention relates to a hydrogel comprising a non-natural polymer comprising a plurality of pendant nucleophilic groups and a crosslinker comprising at least two pendant electrophilic groups. Another aspect of the invention relates to a hydrogel comprising a non-natural polymer comprising a plurality of pendant electrophilic groups and a crosslinker comprising at least two pendant nucleophilic groups. Yet another aspect of the invention relates to a method for reducing lung volume in a patient comprising the step of administering a hydrogel composition as described herein. Further, hydrogels of the invention may be used to achieve pleurodesis, seal brochopleural fistulas, seal an air leak in a lung, achieve hemostasis, tissue sealing (e.g., blood vessels, internal organs), or any combination thereof. In certain embodiments, the compositions and methods described herein are intended for use in the treatment of patients with emphysema. 149-. (canceled)50. A method of attaching a first tissue to a second tissue of a patient in need thereof , comprising the step of applying to said first tissue or said second tissue or both an effective amount of a hydrogel , wherein said hydrogel is prepared from(a) a first non-natural polymer and a first cross-linker; said first non-natural polymer comprises a plurality of pendant first nucleophilic groups; and said first cross-linker comprises at least two pendant first electrophilic groups; or(b) a second non-natural polymer and a second cross-linker; said second non-natural polymer comprises a plurality of second electrophilic groups; and said second cross-linker comprises at least two pendant second nucleophilic groups,thereby attaching said first tissue to said second tissue.5155-. (canceled)56. The method of claim 50 , wherein said hydrogel is prepared from a first non-natural polymer and a first cross-linker; and said first nucleophilic groups are selected from the group consisting of alcohols claim 50 , amines ...

Means for Controlled Sealing of Endovascular Devices

Expandable sealing means for endoluminal devices have been developed for controlled activation. The devices have the benefits of a low profile mechanism (for both self-expanding and balloon-expanding prostheses), contained, not open, release of the material, active conformation to the “leak sites” such that leakage areas are filled without disrupting the physical and functional integrity of the prosthesis, and on-demand, controlled activation, that may not be pressure activated.

Methods of using in situ hydration of hydrogel articles for sealing or augmentation of tissue or vessels

Pharmaceutically acceptable hydrogel polymers of natural, recombinant or synthetic origin, or hybrids thereof, are introduced in a dry, less hydrated, or substantially deswollen state and rehydrate in a physiological environment to undergo a volumetric expansion and to affect sealing, plugging, or augmentation of tissue, defects in tissue, or of organs. The hydrogel polymers may deliver therapeutic entities by controlled release at the site. Methods to form useful devices from such polymers, and to implant the devices are provided.

Bioadhesive for Soft Tissue Repair

The present invention provides compositions and methods for repair and reconstruction of defects and injuries to soft tissues. Some aspects of the invention provide tissue adhesives comprising a hybrid hydrogel by using a naturally derived polymer, gelatin and a synthetic polymer, polyethylene glycol, wherein the hydrogel is biocompatible, biodegradable, transparent, strongly adhesive to corneal tissue, and have a smooth surface and biomechanical properties similar to the cornea.

Composition for hemostasis and container comprising same

The present invention relates to a composition for hemostasis which contains collagen, stabilizer, and thrombin, and a container including the same. The present invention is applicable to a bleeding patient requiring emergency treatment with a simple method of use. There is no toxicity and no problem of blood infection. A biodegradation rate is fast. In this regard, the present invention achieves an excellent hemostatic effect. Therefore, the composition for hemostasis is useful as a hemostat. 1. A composition for hemostasis comprising collagen;stabilizer; andthrombin,wherein the stabilizer is disposed between the collagen and the thrombin so that the collagen and the thrombin are separated from each other.2. The composition of claim 1 , wherein the collagen is crosslinked collagen.3. The composition of claim 2 , wherein the crosslinked collagen is prepared using a preparing method including(S1) a step of treating the collagen with ethanol or methanol,(S2) a step of preparing collagen solution having pH 2 to pH 4 by adding acid to the collagen treated in the step (S1),(S3) a step of preparing esterified collagen by performing centrifugation on the collagen solution prepared in the step (S2) after bringing the collagen solution into a neutral state,(S4) a step of preparing the crosslinked collagen by adding a crosslinking agent to esterified collagen prepared in the step of (S3), and(S5) a step of performing freeze drying on the crosslinked collagen prepared in the step (S4) after the crosslinked collagen is dispersed into purified water.4. The composition of claim 2 , wherein a molecular weight of the crosslinked collagen is 100 claim 2 ,000 to 1 claim 2 ,000 claim 2 ,000 Dalton.5. The composition of claim 1 , wherein the collagen is included as much as 40 to 97 weight % in a gross weight of the composition for hemostasis.6. The composition of claim 1 , wherein the stabilizer is at least one selected from a group consisting of albumin (human serum albumin) claim 1 , ...

HYDROGELS AND USE THEREOF IN ANASTOMOSIS PROCEDURES

This disclosure provides novel hydrogels that can undergo multiple gel-sol transitions and methods of making and using such hydrogels, particularly in anastomosis procedures. The peptide hydrogels comprising a fibrillar network of peptides that are in an amphiphilic β-hairpin conformation. The peptides comprise photo-caged glutamate residues with a neutral photocage that can be photolytically selectively uncaged to disrupt the fibrillar network and trigger an irreversible gel-sol phase transition of the hydrogel. Isolated peptides for making the disclosed hydrogels are provided, as are methods of using the peptide hydrogels in anastomosis procedures. 1. A peptide hydrogel comprising a fibrillar network of peptides , wherein:the hydrogel undergoes a gel-sol phase transition upon application of shear stress, and a sol-gel phase transition upon removal of the shear stress; andthe peptides are in an amphiphilic β-hairpin conformation and comprise photo-caged glutamate residues with a neutral photocage that can be photolytically selectively uncaged to disrupt the fibrillar network and trigger an irreversible gel-sol phase transition of the hydrogel.2. The peptide hydrogel of claim 1 , wherein:the amphiphilic β-hairpin conformation comprises a β-turn, a first β-strand, a second β-strand, a hydrophobic face, and a hydrophilic face;the assembly of the peptides in the fibrillar network comprises hydrophobic interactions between the hydrophobic faces of the peptides;the first β-strand comprises the photocaged glutamate residue, the second β-strand comprises a glycine residue, and the sidechains of the photocaged glutamate residue and the glycine residue are proximal to each other on the hydrophobic faces of the peptides; anduncaging the photocaged glutamate residues disrupts the hydrophobic interactions between the peptides by exposing negative charges of the glutamate residues, thereby disrupting the fibrillar network and triggering the irreversible gel-sol phase transition ...

Self-Assembling Biomimetic Hydrogels Having Bioadhesive Properties

The disclosure relates to a composition that is liquid at a temperature below the body temperature of a mammal and that solidifies at or above the body temperature of the mammal. The composition includes a thermally-desolubilizable polymer interspersed with a polymeric component of extracellular matrix and an encapsulated form of an amine compound (preferably an aminated component of extracellular matrix) that is de-encapsulated in the body of the mammal. The polymeric component is able to form covalent bonds with amine moieties in the aminated component, in one or more tissues in the body of the mammal, or both. Upon injection off liquid suspension of these components into the body of the mammal, the thermally-desolubilizable polymer condenses, entrapping the polymeric component. The polymeric component binds covalently with a tissue in the body, and the aminated component end-caps the remaining reactive moieties of the polymeric component, forming a matrix at the site of injection. The disclosure also relates to uses of such compositions for forming a matrix on or within the body of a mammal. The compositions have a variety of uses, such as bioadhesives, as sealants for ruptured tissues, as drug or imaging agent depots, or as mechanical cushions. 1101-. (canceled)102. A method of forming a solidified matrix fixed within the body of a mammal , the method comprising: a) a biocompatible thermally-desolubilizable (TD) polymer selected from the group consisting of poly(ethylene oxides) (PEOs), poly(propylene oxides) (PPOs), copolymers of PEO and poly(lactide acid) (PLA), poly (n-isopropyl acrylamides) (PNIPPAms), mixtures and copolymers thereof, wherein the polymer exists in an extended form below a critical solution temperature (CST) that is lower than the normal body temperature of the mammal and in a condensed form at or above the CST;', 'b) an aminated component of a mammalian extracellular matrix, in a releasable encapsulated form, wherein the aminated component ...

TWO-REACTANT SHEET-SHAPED ADHESIVE/REINFORCEMENT FOR TISSUES

A sheet-shaped tissue adhesive/reinforcement includes a base sheet having biodegradability and a communicative porous structure, and an adhesive resin layer fixed and formed on the base sheet. The adhesive resin layer includes a first reactant made of an aldehyded glycan and a second reactant made of partially carboxylated polylysine, and has a molar ratio of 1 as a ratio of an aldehyde group of the first reactant to an amine group of the second reactant. The adhesive resin layer has a structure of granules derived from powder of the first reactant, and a connecting layer derived from the second reactant. The connecting layer connects the granules to each other and fixes each of the granules onto the base sheet, throughout the sheet-shaped tissue adhesive/reinforcement. 1. A sheet-shaped tissue adhesive/reinforcement comprising:a base sheet having biodegradability and a communicative porous structure; andan adhesive resin layer fixed and formed on the base sheet,the adhesive resin layer includinga first reactant made of aldehyded glycan, anda second reactant made of partially carboxylated polylysine, and the adhesive resin layer havinga molar ratio of 1 as a ratio of an aldehyde group of the first reactant to an amine group of the second reactant,a structure of granules derived from powder of the first reactant, anda connecting layer derived from the second reactant, the connecting layer connecting the granules with each other and fixing each of the granules onto the base sheet, throughout the sheet-shaped tissue adhesive/reinforcement.2. The sheet-shaped tissue adhesive/reinforcement according to claim 1 , whereinthe base sheet is non-woven fabric, woven fabric, knitted fabric, mesh sheet, sponge sheet, or other continuous porous sheet, and has a thickness of 15 μm to 500 μm, andthe adhesive resin layer has a thickness of 100 μm to 800 μm.3. The sheet-shaped tissue adhesive/reinforcement according to claim 1 , wherein the granules derived from the powder of the ...

IMPLANTATION DEVICES INCLUDING HYDROGEL FILAMENTS

Described are devices for implantation comprising a hydrogel filament wherein the hydrogel filament includes a low molecular weight ethylenically unsaturated macromer, an ethylenically unsaturated monomer, and a visualization agent. Methods of making and using these devices are also described. 1. A device for implantation comprising:a hydrogel filament attached to a coupler wherein the coupler is attached to a pusher,wherein the hydrogel filament includes a low molecular weight ethylenically unsaturated macromer; an ethylenically unsaturated monomer; and a visualization agent,wherein said device contains no support members.2. The device of claim 1 , wherein said macromer has a molecular weight of about 100 grams/mole to about 5000 grams/mole.3. The device of claim 1 , wherein said macromer comprises polyethylene glycol claim 1 , propylene glycol claim 1 , poly(tetramethylene oxide) claim 1 , poly(ethylene glycol) diacrylamide claim 1 , poly(ethylene glycol) diacrylate claim 1 , poly(ethylene glycol) dimethacrylate claim 1 , derivatives thereof claim 1 , or combinations thereof.4. The device of claim 1 , wherein said visualization agent comprises an aromatic ring having a single unsaturation point and at least one iodine atom.5. The device of claim 1 , wherein said visualization agent comprises barium sulfate claim 1 , gadolinium claim 1 , or iron oxide.6. The device of claim 5 , wherein said visualization agent is barium sulfate.7. The device of claim 1 , wherein said ethylenically unsaturated monomer and said visualization agent comprise 2 claim 1 ,4 claim 1 ,6-triiodophenyl penta-4-enoate claim 1 , 5-acrylamido-2 claim 1 ,4 claim 1 ,6-triiodo-n claim 1 ,n′-bis-(2 claim 1 ,3 dihydroxypropyl) isophthalamide claim 1 , derivatives thereof claim 1 , or combinations thereof.8. The device of claim 1 , wherein said macromer and said monomer are crosslinked with N claim 1 ,N claim 1 ,N′ claim 1 ,N′-tetramethylethylenediamine claim 1 , ammonium persulfate claim 1 , ...

Adhesive Composition

The present invention relates to an adhesive composition applicable to skin comprising: (i) a polar oil or fat including (a) at least one triglyceride and/or (b) at least one fatty acid of the formula R—COH, wherein R is a Cto Calkyl group; and (ii) at least one homopolymer, and/or copolymer. This invention also relates to a medical adhesive device including such adhesive composition. 2. (canceled)3. (canceled)4. (canceled)5. The adhesive composition of further comprising at least one tackifier.6. The adhesive composition of claim 5 , wherein the tackifier is selected from the group consisting of natural rosin claim 5 , modified rosin claim 5 , glycerol ester of natural rosin claim 5 , glycerol ester of modified rosin claim 5 , pentaerythritol ester of natural rosin claim 5 , pentaerythritol ester of modified rosin claim 5 , phenolic-modified terpene resin claim 5 , aliphatic petroleum hydrocarbon resin claim 5 , and cycloaliphatic resin.7. (canceled)8. (canceled)9. The adhesive composition of claim 1 , wherein the base polymer comprises at least two immiscible monomers.10. The adhesive composition of further comprising a hydrophilic fluid-absorbing gum or gel-thickener claim 1 , wherein the gum or gel-thickener is cationic claim 1 , anionic claim 1 , or non-ionic.11. The adhesive composition of claim 10 , wherein the gel-thickener is a water soluble or swellable hydrocolloid or a mixture thereof.12. The adhesive composition of claim 11 , wherein the gel-thickener is selected from a group consisting of carboxymethylcellulose claim 11 , hydroxyethylcellulose (HEC) claim 11 , hydroxypropylcellulose (HPC) claim 11 , pectin claim 11 , carrageenan claim 11 , and gelatin.13. A medical adhesive device comprising an adhesive composition comprising coconut oil claim 11 , a mineral oil claim 11 , and a base polymer.14. The adhesive device of claim 13 , wherein the adhesive composition further comprises a tackifier.15. The adhesive device of claim 14 , wherein the tackifier is ...

Temporary Embolization Using Inverse Thermosensitive Polymers

One aspect of the present invention relates to methods of embolizing a vascular site in a mammal comprising introducing into the vasculature of a mammal a composition comprising an inverse thermosensitive polymer, wherein said inverse thermosensitive polymer gels in said vasculature, which composition may be injected through a small catheter, and which compositions gel at or below body temperature. In certain embodiments of the methods of embolization, said composition further comprises a marker molecule, such as a dye, radiopaque, or an MRI-visible compound. 1. A method of temporarily embolizing a vascular site in a mammal , comprising the step of:introducing into the vasculature of a mammal a composition comprising an inverse thermosensitive polymer, wherein said inverse thermosensitive polymer gels in said vasculature, thereby temporarily embolizing a vascular site of said mammal.2. The method of claim 1 , wherein said mammal is a human.3. The method of claim 1 , wherein the transition temperature of said inverse thermosensitive polymer is between about 10 C and about 40 C.4. The method of claim 1 , wherein the volume of the inverse thermosensitive polymer between its transition temperature and physiological temperature is between about 80% and about 150% of the volume of the inverse thermosensitive polymer below its transition temperature.5. The method of claim 1 , wherein said inverse thermosensitive polymer is a block copolymer claim 1 , random copolymer claim 1 , graft polymer claim 1 , or branched copolymer.6. The method of claim 1 , wherein said inverse thermosensitive polymer is a block copolymer.7. The method of claim 1 , wherein said inverse thermosensitive polymer is a polyoxyalkylene block copolymer.8. The method of claim 1 , wherein said inverse thermosensitive polymer is a poloxamer or poloxamine.9. The method of claim 1 , wherein said inverse thermosensitive polymer is a poloxamer.10. The method of claim 1 , wherein said inverse thermosensitive ...

Adhesive Composition

The invention is directed to an adhesive complex coacervate composition, to a method of physically crosslinking an adhesive complex coacervate composition, to a method for adhering a tissue defect in a subject, and to the use of an adhesive complex coacervate composition. The adhesive complex coacervate composition of the invention comprises a polycation and a polyanion, wherein said polycation and polyanion together comprise on average at least two thermoresponsive moieties per polymer chain, said thermoresponsive moieties exhibiting a lower critical solution temperature, wherein said polycation comprises 5-70 mol % of thermoresponsive moieties and/or wherein said polyanion comprises 5-70 mol % of thermoresponsive moieties, and wherein said polycation and/or said polyanion is a graft or block copolymer comprising said thermoresponsive moieties.

LIQUID EMBOLIC AGENT COMPOSITION

Provided is a liquid embolic agent composition capable of solving problems of conventional embolic agents, which can be used in a treatment of a vascular disease such as cerebral aneurysm. The problems are solved by a liquid embolic agent composition characterized in containing a hydrogel forming component having a calcium ion entrapping ability, and an anti-biodegradation component. The hydrogel forming component having a calcium ion entrapping ability is at least one kind of acidic polysaccharide selected from the group consisting of alginate, gellan gum, carrageenan, and carboxymethyl cellulose salt; and the anti-biodegradation component is at least one kind selected from the group consisting of hydroxypropyl methylcellulose, methylcellulose, polyvinyl alcohol, polyallylamine, poly-N-vinyl acetamide, and cellulose acetate. 19-. (canceled)10. A liquid embolic agent composition which comprises:a hydrogel forming component having a calcium ion entrapping ability; andan anti-biodegradable component,wherein the hydrogel forming component having a calcium ion entrapping ability comprises sodium alginate and gellan gum,wherein the anti-biodegradable component is hydroxypropyl cellulose, andwherein the liquid embolic agent composition is in a liquid state in vitro, and gelates by reacting with calcium ions in blood to exhibit a bioadhesiveness in vivo.11. The liquid embolic agent composition according to claim 10 , further comprising a coagulation promoting component claim 10 , wherein the coagulation promoting component is at least one selected from the group consisting of colloidal silica claim 10 , poly(N claim 10 ,N-dimethyl) acrylamide claim 10 , an enzyme preparation for food processing claim 10 , poly-L-lysine hydrobromide claim 10 , poly-L-glutamic acid sodium salt claim 10 , chitosan claim 10 , and silk fibroin.12. The liquid embolic agent composition according to claim 10 , which is used for treating cerebral aneurysm.13. The liquid embolic agent composition ...

Hydrocolloid Wound Dressings with Increased WVTR

Hydrocolloid compositions, wound dressings, methods of using such compositions and such wound dressings, and methods of forming such hydrocolloid compositions, wherein the hydrocolloid compositions include a hydrophobic, unsaturated, elastomeric polymer; a hydrocolloid absorbent; and a hydrophilic polymer including an unsaturated polymer backbone having polyalkylene ether groups bonded thereto. 1. A hydrocolloid composition comprising:a hydrophobic, unsaturated, elastomeric polymer;a hydrocolloid absorbent; anda hydrophilic polymer comprising an unsaturated polymer backbone having polyalkylene ether groups bonded thereto, wherein the hydrophilic polymer is present in an amount that increases the WVTR of the hydrocolloid composition relative to the same hydrocolloid composition without the hydrophilic polymer.2. The hydrocolloid composition of wherein the hydrophobic and hydrophilic polymers are crosslinked to provide the composition with a crosslinked matrix comprising partial unsaturation.3. The hydrocolloid composition of which is in the form of an adhesive.4. The hydrocolloid composition of which is in the form of a pressure sensitive adhesive.5. (canceled)6. The hydrocolloid composition of wherein the hydrophobic claim 1 , unsaturated claim 1 , elastomeric polymer is present in an amount of 20-50 wt-% claim 1 , based on the total weight of the composition.7. The hydrocolloid composition of wherein the hydrophilic polymer is present in an amount of 0.5-20 wt-% claim 1 , based on the total weight of the composition.8. The hydrocolloid composition of wherein the hydrocolloid absorbent is present in an amount of 5-60 wt-% claim 1 , based on the total weight of the composition.9. The hydrocolloid composition of wherein the polyalkylene ether groups are derived from a hydrophilic polyalkylene oxide-containing compound.10. The hydrocolloid composition of wherein the hydrophilic polyalkylene oxide-containing compound comprises ethylene oxide units and optionally co- ...

WATER-RICH ADHERENT GEL, COMPOSITION FOR MANUFACTURING WATER-RICH ADHERENT GEL, AND ELECTRODE PAD

The present invention provides an adhesive, high water content gel that does not cause about generation problem even when used as a patient plate for electrosurgical units through which high current flows and that is excellent adhesion, as well as an electrode pad including the gel. The present invention relates to an adhesive, high water content hydrogel containing a polymer matrix that includes a copolymer of a polymerizable monomer and a crosslinkable monomer, water, a polyhydric alcohol, an electrolyte, polyacrylic acid, and polyvinyl alcohol, the hydrogel containing, based on 100% by weight of the total hydrogel, 40-70% by weight of water, 1.0-5.0% by weight of polyacrylic acid, and 0.5-5.0% by weight of polyvinyl alcohol, and being produced by copolymerization. An electrode pad is also obtained by coating a conductive layer formed on a base film with the adhesive, high water content hydrogel. 1. An adhesive , high water content hydrogel , comprising:a polymer matrix comprising a copolymer of a polymerizable monomer and a crosslinkable monomer;water;a polyhydric alcohol;an electrolyte;polyacrylic acid; andpolyvinyl alcohol,the hydrogel comprising, based on 100% by weight of the total hydrogel, 40% to 70% by weight of water, 1.0% to 5.0% by weight of polyacrylic acid, and 0.5% to 5.0% by weight of polyvinyl alcohol.2. The adhesive claim 1 , high water content hydrogel according to claim 1 ,wherein the polymer matrix is produced by copolymerization using an amphiphilic monomer as part of the polymerizable monomer in an amount of 0.5% to 5.0% by weight based on 100% by weight of the total hydrogel.3. The adhesive claim 2 , high water content hydrogel according to claim 2 ,wherein the amphiphilic monomer is N,N-dimethyl(meth)acrylamide.4. The adhesive claim 1 , high water content hydrogel according to claim 1 ,wherein the hydrogel comprises 45% to 65% by weight of water.5. The adhesive claim 1 , high water content hydrogel according to claim 1 ,wherein the ...

EMBOLIC MICROSPHERES

In some aspects, the disclosure pertains to injectable particles that contain at least one pH-altering agent that is configured to be released from the injectable particles in vivo, upon embolization of an intratumoral artery of a tumor with the injectable particles. In certain instances, the pH-altering agent may be a basic agent having a pH value of 7.5, a buffering agent having a pKa value of 7.6 or more, or both. Other aspects of the disclosure pertain to preloaded containers containing such injectable particles and methods of using such injectable particles. 1. Injectable particles comprising at least one pH-altering agent that is configured to be released from the injectable particles in vivo upon embolization of an intratumoral artery of a tumor with the injectable particles.2. The injectable particles of claim 1 , wherein the injectable particles are configured such that claim 1 , upon embolization of the intratumoral artery of the tumor with the injectable particles claim 1 , the injectable particles release the pH-altering agent such that a microenvironment is created in a vascular bed of the tumor downstream of the injectable particles that has a pH that is higher than a pH that would otherwise exist in the absence of the pH-altering agent.3. The injectable particles of claim 1 , wherein the injectable particles are spherical or non-spherical particles.4. The injectable particles of claim 1 , wherein the injectable particles range from 20 to 1500 microns in diameter.5. The injectable particles of claim 1 , wherein the pH-altering agent is (a) a basic agent having a pH value of 7.5 or more claim 1 , (b) a buffering agent having a pKa value of 7.6 or more claim 1 , or a combination of (a) and (b).6. The injectable particles of claim 1 , wherein the pH-altering agent is (a) a basic agent having a pH value ranging from 7.5 to 10 claim 1 , (b) a buffering agent having a pKa value ranging from 8 to 35 claim 1 , or (c) a combination of (a) and (b).7. The ...

Method of forming and using a hemostatic hydrocolloid

A method and system for forming a hemostatic hydrocolloid for dispensing into a wound site includes a polymer of oxidized derivatized esterified cellulose in solid form comprising a chain of monomers, wherein, for a first plurality of the monomers in the chain: R is —OCH 2 (COO)CH 2 CH 3 , R1 is —OCH 2 (COO)CH 2 CH 3 , and R2 is —CH 2 OCH 2 (COO)CH 2 CH 3 ; and wherein, for a second plurality of monomers in the chain: R is —OCH 2 (COO)CH 2 CH 3 , R1 is —OCH 2 (COO)CH 2 CH 3 , and R2 is —(COO)CH 2 CH 3 and a liquid mixed with the polymer to form a hemostatic gel for dispensing into a wound site.

BIOADHESIVE HYDROGELS

A bioadhesive includes a crosslinked biodegradable hydrogel that includes a plurality of oxidized, acrylated or methacrylated, natural polymer. Bioadhesives are natural or synthetic materials that can be used for soft tissue repair to create a seal preventing leakage of biological fluids or to reinforce anatomic integrity as an attractive alternative to sutures and staples. The most widely used bioadhesives are fibrin, cyanoacrylates, and albumin-glutaraldehyde bioadhesives. 1. A bioadhesive comprising: a crosslinked biodegradable hydrogel that includes a plurality of oxidized , acrylated or methacrylated , natural polymer macromers crosslinked with a plurality of branched poly(ethylene glycol) macromers.2. The bioadhesive of claim 1 , wherein the oxidized claim 1 , acrylated or methacrylated claim 1 , natural polymer macromers include a plurality of aldehyde groups that are crosslinked with the branched poly(ethylene glycol) macromers.3. The bioadhesive of claim 1 , wherein the oxidized claim 1 , acrylated or methacrylated claim 1 , natural polymer macromers are polysaccharides claim 1 , which are oxidized so that about 1% to about 50% of the saccharide units therein are converted to aldehyde saccharide units.4. The bioadhesive of claim 1 , wherein acrylate or methacrylate groups of the natural polymer macromers are crosslinked so that the hydrogel is dual crosslinked.5. The bioadhesive of claim 1 , the oxidized claim 1 , acrylated or methacrylated claim 1 , natural polymer macromers comprising oxidized claim 1 , acrylated or methacrylated claim 1 , alginates.6. The bioadhesive of claim 1 , wherein the poly(ethylene glycol) macromers are poly(ethylene glycol) amine macromers.7. The bioadhesive of claim 6 , wherein the poly(ethylene glycol) amine macromers are n-arm poly(ethylene glycol) amines claim 6 , where n is an integer greater than 1.8. The bioadhesive of claim 1 , wherein the hydrogel is cytocompatible and claim 1 , upon degradation claim 1 , produces ...

Color-coded and sized loadable polymeric particles for therapeutic and/or diagnostic applications and methods ofpreparing and using the same

Polymeric particles are provided for use in therapeutic and/or diagnostic procedures. The particles include poly[bis(trifluoroethoxy)phosphazene and/or a derivative thereof which may be present throughout the particles or within an outer coating of the particles. The particles may also include a core having a hydrogel formed from an acrylic-based polymer. Such particles may be provided to a user in specific selected sizes to allow for selective embolization of certain sized blood vessels or localized treatment with an active component agent in specific clinical uses. Particles of the present invention may further be provided as color-coded microspheres or nanospheres to allow ready identification of the sized particles in use. Such color-coded microspheres or nanospheres may further be provided in like color-coded delivery or containment devices to enhance user identification and provide visual confirmation of the use of a specifically desired size of microspheres or nanospheres.

CEREBROSPINAL FLUID LEAKAGE OCCLUSION

Methods and materials for treating a cerebrospinal fluid leakage are described herein. One method for treating cerebrospinal fluid leakage includes occluding cerebrospinal fluid leakage by administering an effective amount of a self-assembling peptide solution to a target area of a cerebrospinal fluid leakage, where the self-assembling peptide is between 7 amino acids and 32 amino acids in length and the self-assembling peptide solution forms a hydrogel under physiological conditions. 1. (canceled)2. A method for treating cerebrospinal fluid leakage , the method comprising administering an effective amount of a self-assembling peptide solution to an area of dura associated with the cerebrospinal fluid leakage , wherein the self-assembling peptide is between 7 amino acids and 32 amino acids in length and the self-assembling peptide solution forms a hydrogel under physiological conditions;{'sup': 2', '2, 'wherein the effective amount is approximately 0.1 mL per 1 cmto approximately 5 mL per 1 cmof a site of the cerebrospinal fluid leakage; and'}the self-assembling peptide is about 0.1 to about 3.5 w/v % of the self-assembling peptide solution.3. The methods of claim 1 , wherein the target area comprises an area of dura associated with cerebrospinal fluid leakage.4. The method of claim 1 , wherein the hydrogel mitigates cerebrospinal fluid leakage.5. The method of claim 1 , wherein the hydrogel substantially prevents cerebrospinal fluid leakage.6. The method of claim 2 , wherein the self-assembling peptide comprises about 12 to about 16 amino acids that alternate between hydrophobic and-a hydrophilic amino acids.7. The method of claim 2 , wherein the self-assembling peptide comprises a sequence selected from RADA (SEQ ID NO:1) claim 2 , IEIK (SEQ ID NO:2) claim 2 , TTTT (SEQ ID NO:3) claim 2 , ATAT (SEQ ID NO:4) claim 2 , TVTV (SEQ ID NO:5) claim 2 , ASAS (SEQ ID NO:6) claim 2 , SSSS (SEQ ID NO:7) claim 2 , VVVTTTT (SEQ ID NO:8) claim 2 , and a combination thereof.8. ...

POLY (IONIC LIQUID) COMPOSITIONS AND THEIR USE AS TISSUE ADHESIVES

The present invention relates to the discovery of methods of treating a wound in a subject in need thereof. In certain embodiments, the method comprises contacting the wound with a composition comprising gelatin methacrylate and choline acrylate, and then polymerizing the composition to form a polymerized composition having a plurality of choline acrylate functionalized gelatin methacrylate units. 1. A method of treating a wound in a subject in need thereof , the method comprising:(a) contacting the wound with a composition comprising:a polymer selected from the group consisting of gelatin methacrylate (GelMa) and poly(ethylene glycol) diacrylate (PEGDA);choline acrylate; andat least one photoinitiator; and(b) exposing the composition to at least one wavelength of light capable of activating the at least one photoinitiator, thereby polymerizing the composition.2. The method of claim 1 , wherein the composition comprises about 1:4 to about 4:1 choline acrylate to polymer.3. (canceled)4. The method of claim 1 , wherein at least one photoinitiator is selected from the group consisting of eosin Y claim 1 , 2-hydroxy-2-methylpropiophenone claim 1 , 2-methyl-4′-(methylthio)-2-morpholinopropiophenone claim 1 , lithium phenyl-2 claim 1 ,4 claim 1 ,6-trimethylbenzoylphosphinate (LAP) claim 1 , and 2-hydroxy-4′-(2-hydroxyethoxy)-2-methylpropiophenone (Irgacure).5. The method of claim 1 , wherein the composition further comprises at least one additional compound selected from the group consisting of triethanolamine (TEOA) and N-vinylcaprolactam (VC).6. (canceled)7. The method of claim 1 , wherein the composition comprises about 10% to about 20% (w/v) choline acrylate.8. The method of claim 1 , wherein the composition comprises about 10% to about 30% (w/v) polymer.9. The method of claim 4 , wherein the composition comprises at least one of:about 0.1 mM eosin Y;0.5% (w/v) LAP;about 1.5% (w/v) TEOA; orabout 1% (w/v) VC.10. (canceled)11. (canceled)12. (canceled)13. The method of ...

TREATMENT FOR BILE LEAKAGE

Materials and methods for treating bile leakage are disclosed. A peptide comprising between about 7 amino acids to about 32 amino acids may be introduced to a target site. The peptide may undergo self-assembly upon adjustment of a pH level of the solution to a physiological pH level. 1. A method of treating a bile leakage in a subject comprising:positioning an end of a delivery device in a target area of the bile leakage in which an occlusion is desired;administering through the delivery device a solution comprising a self-assembling peptide comprising between about 7 amino acids and about 32 amino acids in an effective amount and in an effective concentration to form a hydrogel under conditions surrounding the bile leakage to provide an occlusion of the bile leakage;removing the delivery device from the target area of the bile leakage.2. The method of claim 1 , further comprising visualizing a region comprising at least a portion of the target area surrounding the bile leakage.3. The method of claim 2 , wherein visualizing the region comprises visualizing the region during at least one of:identifying the target area of the bile leakage;positioning the end of the delivery device in the target area;administering the solution;removing the delivery device; andmonitoring the bile leakage after removing the delivery device.4. The method of claim 3 , wherein visualizing the region provides for selective administration of the solution to the target area of the bile leakage.5. The method of claim 3 , further comprising visualizing the region in a time period of about one minute subsequent to administering the solution.6. The method of claim 5 , further comprising visualizing the region in a time period of about three minutes subsequent to administering the solution.7. The method of claim 6 , further comprising visualizing the region in a time period of about one week subsequent to administering the solution.8. The method of claim 1 , wherein at least one of the effective ...

APPARATUS AND METHODS FOR SEALING A VASCULAR PUNCTURE

A sealant for sealing a puncture through tissue includes a first section, e.g., formed from freeze-dried hydrogel, and a second section extending from the distal end. The second section may be formed from PEG-precursors including PEG-ester and PEG-amine, e.g., in an equivalent ratio of active group sites of PEG-ester/PEG-amine greater than one-to-one, e.g., such that excess esters may provide faster activation upon contact with physiological fluids and enhance adhesion of the sealant within a puncture. At least some of the precursors remain in an unreactive state until exposed to an aqueous physiological environment, e.g., within a puncture, whereupon the precursors undergo in-situ cross-linking to provide adhesion to tissue adjacent the puncture. For example, the PEG-amine precursors may include the free amine form and the salt form. The free amine form at least partially cross-links with the PEG-ester and the salt form remains in the unreactive state in the sealant before introduction into the puncture. 140-. (canceled)41. A sealant for sealing a puncture through tissue , comprising:a mass of PEG precursors comprising PEG-ester precursors and PEG-amine precursors, the PEG-amine precursors including a free-amine form of PEG-amine precursors and a salt form of PEG-amine precursors;wherein the sealant is provided such that the free-amine form of PEG-amine precursors are at least partially cross-linked with the PEG-ester precursors, and the salt form of PEG-amine precursors remain in an unreactive state until exposed to an aqueous physiological environment, whereupon the salt form of PEG-amine precursors undergo in-situ cross-linking with the PEG-ester precursors to provide adhesion to tissue adjacent the puncture.42. The sealant of claim 41 , wherein a ratio of active group sites of PEG-ester precursors/salt form of PEG-amine precursors/free-amine form of PEG-amine precursors is between about 50/42/8 and 50/48/2.43. The sealant of claim 41 , wherein a ratio of active ...

CARBON-BASED COMPOSITIONS USEFUL FOR OCCLUSIVE MEDICAL DEVICES AND METHODS OF MAKING AND USING THEM

An occlusive device and a method of embolizing or occluding a bodily lumen by injecting or otherwise implanting the occlusive device are described. The device includes a polymer or polymer composition and a carbon-based material or nanomaterial such as graphene. The device may be used for sterilizing a human or animal by implanting the device into the vas deferens, fallopian tubes, or uterus, but may also be used to occlude any other bodily ducts, interstitial space, or organs. 1. A composition comprising:a carbon-based nanomaterial or carbon allotrope, a polymer or network forming agent, and a solvent,wherein the carbon-based nanomaterial or carbon allotrope is present in the composition at a concentration which enhances the efficacy of the composition as an occlusive agent upon administration into a body lumen.2. The composition of claim 1 , wherein the composition is a hydrogel or forms a hydrogel in situ upon administration into a body lumen.3. The composition of claim 1 , wherein the carbon-based nanomaterial or carbon allotrope is present in the composition at a concentration which enhances the efficacy of the composition as a contraceptive agent.4. The composition of claim 3 , wherein the carbon-based nanomaterial or carbon allotrope is present in the composition at a concentration that decreases the fertility claim 3 , motility claim 3 , and/or viability of sperm cells.5. The composition of claim 1 , wherein the carbon-based nanomaterial or carbon allotrope is present in the composition at a concentration that increases the hardness and/or durability of the hydrogel.6. The composition of claim 1 , wherein the carbon-based nanomaterial or carbon allotrope is present in the composition at a concentration that improves the mechanical properties of the hydrogel.7. The composition of claim 1 , wherein the carbon-based nanomaterial or carbon allotrope is present in the composition at a concentration which alters the viscosity of the hydrogel.8. The composition of ...

BUFFERED ADHESIVE COMPOSITIONS FOR SKIN-ADHERING MEDICAL PRODUCTS

Provided are buffered adhesive compositions comprising a high molecular weight non-neutralized polymeric acid and a high molecular weight partially neutralized polymeric acid and products such as wound dressings and ostomy skin barriers incorporating the compositions. 1. An ostomy skin barrier comprising:a first adhesive that includes a high molecular weight polymeric buffer composition; anda second adhesive, that does not contain a high molecular weight polymeric buffer composition.2. The ostomy skin barrier of claim 1 , wherein the second adhesive has a lower absorptive capacity than the first adhesive.3. The ostomy skin barrier of claim 1 , wherein the second adhesive includes a hydrocolloid.4. The ostomy skin barrier of claim 1 , wherein the non-neutralized high molecular weight polymeric acid is high molecular weight polyacrylic acid and the partially neutralized high molecular weight polymeric acid is partially neutralized high molecular weight polyacrylic acid.5. The ostomy skin barrier of claim 1 , wherein the first adhesive includes 40 wt. % of polyisobutylene claim 1 , 16 wt. % of styrene-isoprene-styrene copolymer claim 1 , 5 wt. % of liquid PIB claim 1 , 4 wt. % of polyethelyene fibers claim 1 , 20 wt. % of cross linked polyacrylic acid claim 1 , and 15 wt. % of cross linked partially neutralized polyacrylic acid.6. The ostomy skin barrier of claim 1 , wherein the second adhesive includes 55.5 wt. % polyisobutylene claim 1 , 14.5 wt. % of styrene-isoprene-styrene copolymer claim 1 , 5 wt. % of polyethylene fibers claim 1 , 8.3 wt. % of pectin claim 1 , and 16.7 wt. % of CMC.7. The ostomy skin barrier of claim 1 , wherein the first adhesive includes 40 wt. % of polyisobutylene claim 1 , 16 wt. % of styrene-isoprene-styrene copolymer claim 1 , 5 wt. % of liquid PIB claim 1 , 4 wt. % of polyethelyene fibers claim 1 , 20 wt. % of cross linked polyacrylic acid claim 1 , and 15 wt. % of cross linked partially neutralized polyacrylic acid and the second ...

SOFT TISSUE ADHESIVE COMPOSITION OF ALPHA-TCP AND PHOSPHORYLATED AMINO ACID

The present invention relates to a soft tissue adhesive comprising an aqueous composition comprising α-TCP and a phosphorylated amino acid. The composition has improved mechanical strength and is easily applied to the tissue. 1. A soft tissue adhesive comprising an aqueous solution , α-TCP and a phosphorylated amino acid.2. The adhesive according to wherein the amount of phosphorylated amino acid is 50-85 wt %.3. The adhesive according to wherein the amount of phosphorylated amino acid is 60-80 wt %.4. The adhesive according to wherein the amount of phosphorylated amino acid is 15-37 wt %.5. The adhesive according to wherein the amount of phosphorylated amino acid is 15-30 wt %.6. The adhesive according to wherein at least 95 wt % of the composition comprises an aqueous solution claim 1 , α-TCP and a phosphorylated amino acid.7. The adhesive according to wherein at least 98 wt % of the composition comprises an aqueous solution claim 1 , α-TCP and a phosphorylated amino acid.8. The adhesive according to wherein at least 98 wt % of the composition comprises an aqueous solution claim 1 , α-TCP and wherein the amount of phosphorylated amino acid is 60-80 wt %.9. The adhesive according to wherein at least 98 wt % of the composition comprises an aqueous solution claim 1 , α-TCP and wherein the amount of phosphorylated amino acid is 15-35%.10. The adhesive according to wherein the phosphorylated amino acid is phosphorylated serine.11. The adhesive according to to wherein the composition does not comprise a silicate compound.12. The adhesive according to to wherein the aqueous solution is water.13. The adhesive according to to wherein the composition further comprises a hydrogel.14. (canceled)15. A method of adhering a first soft tissue to a second soft tissue using the tissue adhesive according to comprising:a. applying the tissue adhesive to the first soft tissue or to the second soft tissue and optionally leave it for a suitable period of time;b. bringing the first ...

CHITOSAN AND POLYETHYLENE GLYCOL COPOLYMERS AND METHODS AND DEVICES FOR USING SAME FOR SEALING A VASCULAR PUNCTURE

A sealant is provided for sealing a puncture through tissue that comprises an elongate first section including a proximal end, a distal end, and a cross-section sized for delivery into a puncture through tissue, and a second section extending from the distal end of the first section. The first section may be formed from a freeze-dried hydrogel that expands when exposed to physiological fluid within a puncture. The first section comprises chitosan and at least one additional polymer. The second section may be formed from a solid mass of non-freeze-dried, non-cross-linked hydrogel precursors. The precursors are in an unreactive state until exposed to an aqueous physiological environment, whereupon the precursors undergo in-situ crosslinking with one another to provide an adhesive layer bonded to the first section. The second section may further comprise chitosan. Apparatus and methods for delivering the sealant into a puncture through tissue are also provided. 141-. (canceled)42. A vascular sealant comprising a biodegradable polysaccharide having hemostatic and/or procoagulative properties, and a mixture of amine modified polyethylene glycol (PEG) and ester modified PEG polymers,', 'wherein the polysaccharide is covalently bound to the mixture of PEG polymers; and, 'a first elongated section with a proximal and distal end comprising a copolymer with'}a second section extending from the distal end of the first section comprising non-cross-linked precursors of amine modified PEG and ester modified PEG.43. The vascular sealant of claim 42 , wherein the biodegradable polysaccharide is deacetylated chitin.44. The vascular sealant of claim 42 , wherein the biodegradable polysaccharide is chitosan.45. The vascular sealant of claim 42 , wherein the copolymer in the first section forms a hydrogel.46. The vascular sealant of claim 42 , wherein amine modified PEG and ester modified PEG are present in a molar ratio of between 4:1 and 1:4.47. The vascular sealant of claim 42 , ...

PRESSURE-SENSITIVE HYDROGEL AND METHOD OF USE

Embodiments of the disclosure may include a pressure sensitive hydrogel composition. The composition may include a liquid solvent, a polymer, and an acid gas. The composition may be capable of having a fluid phase in which the acid gas is dissolved in the solvent and the polymer is dissolved in the solvent, and the composition may be capable of having a gel phase in which the acid gas is not dissolved in the liquid solvent and the polymer is precipitated out of the solvent. The composition may also include a chemical compound or a pharmaceutical agent that can be released after the composition is delivered to a target tissue region. 1. A method of making a pressure-sensitive hydrogel composition , comprising:exposing a polymer and a solvent to an acid gas; andsubjecting the polymer, the solvent, and the acid gas to an increase in pressure to dissolve the acid gas in the solvent to form an acidic solution, causing the polymer to dissolve into the solution to form a fluid under a first pH,subjecting the fluid to a decrease in pressure causes the acid gas to come out of solution to form a gel under a second pH higher than the first pH,wherein the fluid and the gel are reversibly interchangeable.2. The method of claim 1 , wherein the polymer is selected from the group consisting of collagen claim 1 , gelatin claim 1 , cellulose claim 1 , hyaluronic acid claim 1 , casein claim 1 , alginate claim 1 , fibrinogen claim 1 , thrombin claim 1 , and any combination thereof.3. A method of repairing tissue claim 1 , comprising:{'claim-ref': {'@idref': 'CLM-00001', 'claim 1'}, 'delivering and pressurizing the pressure-sensitive hydrogel composition of to a target tissue region; and'} wherein the hydrogel composition comprises the polymer, the solvent and the acid gas,', 'wherein the pressurized hydrogel composition is in a liquid state, and', 'wherein the depressurized hydrogel composition is in a gel state., 'depressurizing the hydrogel composition,'}4. The method of claim 3 , ...

Systems, Devices, Components and Methods for Improved Acoustic Coupling Between a Bone Conduction Hearing Device and a Patient's Head or Skull

Disclosed are various embodiments of systems, devices, components and methods for improving acoustic coupling between a bone conduction hearing device (BCHD) and a patient's head or skull. Such systems, devices, components and methods include disposing a gel or paste between the BCHD and the patient's skin, hair and/or skull. The gel or paste improves the transmission of acoustic signals generated by a transducer in the BCHD to the patients head or skull by providing a more efficient and improved intermediary acoustic medium for the transmission of acoustic signals to the patient's head or skull. 1. A method of improving acoustic coupling between a bone conduction hearing device (BCHD and a patient's head or skull , the BCHD comprising a transducer configured to generate sound signals for transmission to the patient's skull , the method comprising:applying an aqueous gel or paste to a bottom surface of the BCHD, andattaching, securing or magnetically coupling the BCHD to or against the patient's head or skull;wherein at least portions of the gel or paste are operably disposed between the bottom surface of the BCHD and the patient's head or skull thereby to improve acoustic coupling and transmission of the sound signals generated the transducer to the patient's skull.2. The method of claim 1 , wherein a baseplate or spacer is operably connected to or forms a portion of the BCHD and is operably attached to or forms a portion of the transducer.3. The method of claim 1 , wherein the transducer is an electromagnetic (“EM”) transducer or a piezoelectric transducer.4. The method of claim 1 , wherein the BCHD is a magnetic BCHD.5. The method of claim 4 , wherein a magnetic implant is attached to or in the patient's skull beneath the patient's skin at an implant location claim 4 , and is configured to magnetically couple to the magnetic BCHD.6. The method of claim 5 , wherein the magnetic BCHD is magnetically attached to the patient's skull over the implant location.7. The ...

FLOWABLE HEMOSTATIC GEL COMPOSITION AND ITS METHODS OF USE

A method of inhibiting bleeding from an open surgical site includes mixing (i) a flowable gel solution comprising a biopolymer dissolved in a first solvent and (ii) a flowable hardener solution comprising a cross-linking agent dissolved in a second solvent to form a flowable hemostatic gel composition. The method also includes applying the flowable hemostatic gel composition to the open surgical site. The cross-linking agent links chains of the biopolymer together to form a solid hydrogel that inhibits bleeding from the surgical site. 1. A method of inhibiting bleeding from an open surgical site , said method comprising:mixing (i) a flowable gel solution comprising a biopolymer dissolved in a first solvent and (ii) a flowable hardener solution comprising a cross-linking agent dissolved in a second solvent to form a flowable hemostatic gel composition; andapplying the flowable hemostatic gel composition to the open surgical site, wherein the cross-linking agent links chains of the biopolymer together to form a solid hydrogel that inhibits bleeding from the surgical site.2. The method of claim 1 , wherein said mixing the flowable gel solution and the flowable hardener solution comprises mixing the flowable gel solution and the flowable hardener solution within a lumen of an injection device claim 1 , and said applying the flowable hemostatic gel composition comprises flowing the flowable hemostatic gel composition out of the lumen of the injection device.3. The method of claim 1 , wherein said mixing the flowable gel solution and the flowable hardener solution comprises mixing the flowable gel solution and the flowable hardener solution prior to introducing the flowable hemostatic gel composition into a lumen of an injection device claim 1 , and said applying the flowable hemostatic gel composition comprises flowing the flowable hemostatic gel composition out of the lumen of the injection device.4. The method of claim 1 , wherein said mixing the flowable gel solution ...

Topical composition for the treatment of mucosal lesions

Topical composition for the treatment of mucosal lesions It relates to a topical composition comprising specific amounts of: a) a hyaluronic acid or a pharmaceutically or veterinary acceptable salt thereof, b) one or more adhesive agents, and c) a non-absorbable antibiotic; to delivery devices comprising it; and to its uses in medicine, in particular, in the treatment and/or prevention of mucosal lesions; in the prevention of postpolypectomy syndrome; as adjuvant therapy to mechanical treatments in gastrointestinal perforations, and as sealant treatment in surgical anastomoses and leaks or fistulas in gastrointestinal tract.

BIOCOMPATIBLE HYDROGEL TREATMENTS FOR RETINAL DETACHMENT

Provided herein are in vivo gelling ophthalmic pre-formulations forming a biocompatible retinal patch comprising at least one nucleophilic compound or monomer unit, at least one electrophilic compound or monomer unit, and optionally a therapeutic agent and/or viscosity enhancer. In some embodiments, the retinal patch at least partially adheres to the site of a retinal tear. Also provided herein are methods of treating retinal detachment by delivering an in vivo gelling ophthalmic pre-formulation to the site of a retinal tear in human eye, wherein the in vivo gelling ophthalmic pre-formulation forms a retinal patch. 116-. (canceled)17. A method of delivering a therapeutic to an eye , the method comprising: administering to the eye a therapeutic agent and a formulation comprising:(a) multi-ARM nucleophilic polyol monomers having more than two nucleophilic arms, wherein each nucleophilic arm comprises a polyethyleneglycol chain and terminates in a nucleophilic group selected from a hydroxyl, thiol, and amino;(b) multi-ARM electrophilic polyol monomers having more than two electrophilic arms, wherein each electrophilic arm comprises a polyethyleneglycol chain and terminates in an electrophilic group selected from epoxide, maleimide, succinimidyl, and an alpha-beta unsaturated ester; and(c) a viscosity enhancer selected from acacia, agar, alginic acid, alginate, bentonite, carbomers, carboxymethylcellulose calcium, carboxymethylcellulose sodium, carrageenan, ceratonia, cetostearyl alcohol, chitosan, colloidal silicon dioxide, cyclomethicone, ethylcellulose, gelatin, glycerin, glyceryl behenate, guar gum, hectorite, hydrogenated vegetable oil type I, hydroxypropyl starch, magnesium aluminum silicate, maltodextrin, polycarbophil, polydextrose, poly(methylvinyl ether/maleic anhydride), polyvinyl acetate phthalate, potassium chloride, propylene glycol alginate, saponite, sodium alginate, sodium chloride, stearyl alcohol, sucrose, sulfobutylether β-cyclodextrin, tragacanth, ...

Tissue repair by stem cell recruitment and differentiation

Provided herein are compositions and methods for healing cartilage tissue defects or injury by forming fibrochondrocyte cells or fibrochondrocyte-like cells from recruited progenitor cells, such as mesenchymal stem cells.

COMPOSITION OF ALPHA-TCP, SILICATE AND PHOSPHORYLATED AMINO ACID

The present invention relates to an aqueous composition comprising an aqueous solution, α-TCP, a silicate compound and a phosphorylated amino acid. The composition has improved mechanical strength and is easily applied and may be used as a tissue adhesive, implant or a filler. 1. An aqueous composition comprising an aqueous solution , a silicate compound , α-TCP and a phosphorylated amino acid;wherein the amount of phosphorylated amino acid is 15-90 wt % of the solid content, the combined amount of silicate compound and α-TCP is 10-85 wt % of the solid content, and wherein the weight ratio of the silicate compound and α-TCP is 1:0.001-100.2. The aqueous composition according to wherein the amount of phosphorylated amino acid is 15-50 wt % of the solid content.3. The aqueous composition according to wherein the amount of phosphorylated amino acid is 20-40 wt % of the solid content.4. The aqueous composition according to wherein the amount of phosphorylated amino acid is 22-35 wt % of the solid content.5. The aqueous composition according to wherein theweight ratio of the silicate compound and α-TCP is 1:0.05-0.4 such as 1:0.1-0.3.6. The aqueous composition according wherein the weight ratio of the silicate compound and α-TCP is 1:5-15 claim 1 , such as 1:9-12.7. The aqueous composition according to whereinthe silicate compound is selected from calcium silicate, sodium silicate and, strontium silicate; zirconium silicate; or a mixture of di- and tricalcium silicate, preferably calcium silicate or a mixture of di- and tricalcium silicate.8. The aqueous composition according to wherein the phosphorylated amino acid is phosphoserine.9. The aqueous composition according to wherein the amount of aqueous solution is 5-20 wt % of the total weight of the composition.10. The aqueous composition according to wherein the composition comprises 20-70 wt % of phosphorylated amino acid and wherein the weightratio of the silicate compound and α-TCP is 1:0.05-0.4 or 1:5-15 and wherein ...

Partially-denatured protein hydrogels

Provided herein are partially-denatured protein (e.g., albumin) hydrogels and methods of manufacture (e.g., pH induction) and use (e.g., drug delivery) thereof.

METHODS OF BREAST SURGERY

Surgical procedures of the breast where an adhesive is applied to fixate a reshaped and/or relocated portion of breast tissue. 1. A method of treating breast tissue , comprising:moving a first portion of breast tissue from a first location to a second location; andapplying an adhesive to retain the first portion of breast tissue at the second location.2. The method of claim 1 , wherein the adhesive is applied to the first portion of breast tissue.3. The method of claim 1 , wherein the adhesive is applied to an anatomical structure at the second location.4. The method of claim 3 , wherein the adhesive is applied to the anatomical structure before the first portion of breast tissue is moved to the second location.5. The method of claim 4 , further comprising contacting the first portion of breast tissue with the anatomical structure.6. The method of claim 2 , wherein the anatomical structure comprises at least one of skin overlying breast tissue claim 2 , breast tissue claim 2 , chest wall claim 2 , periosteum or skin at an upper pole portion of a breast.7. (canceled)8. The method of claim 2 , wherein the adhesive is applied to the first portion of breast tissue after the first portion of breast tissue is moved to the second location.9. The method of claim 1 , wherein the adhesive is applied to a prosthetic.10. The method of claim 9 , wherein the prosthetic is selected from the group consisting of a surgical repair fabric and a breast implant.11. (canceled)12. The method of claim 1 , wherein the second location is anatomically superior to the first location.13. The method of claim 1 , further comprising moving a second portion of breast tissue from a third location to a fourth location; andapplying an adhesive to retain the second portion of breast tissue at the fourth location.14. The method of claim 13 , wherein the second portion of breast tissue is placed adjacent to the first portion of breast tissue.15. The method of claim 14 , further comprising applying an ...

CROSSLINKED GELS COMPRISING POLYALKYLENEIMINES, AND THEIR USES AS MEDICAL DEVICES

One aspect of the present invention generally relates to methods of sealing a wound or tissue plane or filling a void splace. In a preferred embodiment, the wound is an ophthalmic, pleural or dural wound. In certain instances, the compositions used to seal the wound or tissue plane comprises a polyalkyleneimine. In a preferred embodiment, the polyalkyleneimine is polyethyleneimine. Treatment of the polyethyleneimine with a cross-linking reagent causes the polyethyleneimine polymers to polymerize forming a seal. In certain instances, the cross-linking reagent is a polyethylene glycol having reactive terminal groups. In certain instances, the reactive terminal groups are activated esters, such as N-hydroxy succinimide ester. In certain instances, the reactive terminal groups are isocyanates. In certain instances, the polyethyleneimine has a lysine, cysteine, isocysteine or other nucleophilic group attached to the periphery of the polymer. In certain instances, the polyethyleneimine is mixed with a second polymer, such as a polyethylene glycol containing nucleophilic groups. In certain instances, the compositions used to seal the wound or tissue plane are formed by reacting a polyalkyleneimine bearing electrophilic groups with a cross-linking reagent containing nucleophilic groups. In certain instances, the electrophilic groups on the polyalkyleneimine are activated esters, such as N-hydroxy succinimide ester. In certain instances, the compositions used to seal the wound or tissue plane are formed by reacting a polyalkyleneimine bearing photopolymerizable groups with ultraviolet or visible light. Compositions used to seal the wound which contain PEI or a derivative of PEI are found to adhere tightly to the tissue. Other aspects of the present invention relate to methods of filling a void of a patient or adhering tissue. In certain instances, the methods use a polyalkyleneimine. In a preferred embodiment, the polyalkyleneimine is polyethyleneimine. Another aspect of the ...

FUNCTIONALIZED ADHESIVE MEDICAL GEL

A bioadherent substrate includes a medical gel or medical gel precursor having a plurality of reactive members of a specific binding pair attached on or adapted to be attached to a surface of the medical gel, said reactive members being capable of forming covalent bonds with a plurality of complementary reactive members of the specific binding pair via a reaction selected from a Huisgen cycloaddition reaction, a Diels-Alder reaction and a thiol-ene reaction. A method for adhering a medical gel to biological tissue includes providing a medical gel or a medical gel precursor having a plurality of reactive members of a specific binding pair attached on or adapted to be attached to a surface of the medical gel and providing tissue with a plurality of complementary reactive members of the specific binding pair, wherein upon contact of the reactive members on the medical gel with the complimentary reactive members on the tissue, covalent bonds are formed between the reactive members and the complementary reactive members, thus adhering the medical gel to the tissue. 1. A bioadherent substrate comprising a medical gel or medical gel precursor having a plurality of reactive members of a specific binding pair adapted to be attached on a surface of the medical gel , said reactive members being capable of forming covalent bonds with a plurality of complementary reactive members of the specific binding pair via a reaction selected from the group consisting of Huisgen cycloaddition reaction , a Diels-Alder reaction and a thiol-ene reaction.2. The bioadherent substrate according to wherein the medical gel is a hydrogel.3. The bioadherent substrate according to wherein the plurality of reactive members of the specific binding pair are selected from the group consisting of alkynes and azides.4. The bioadherent substrate according to wherein the plurality of reactive members of the specific binding pair form covalent bonds via a reaction catalyzed by copper to activate an alkyne and ...

Ionically Crosslinked Polyelectrolytes as Underwater Adhesives and Controlled Release Vehicles

Underwater adhesive materials, methods of making the same, and methods of using the same are described. 1. A method for controllably releasing a small molecule comprising:adding a small molecule to either (i) a first solution comprising non-polysaccharide polymer having two or more amine groups, or (ii) a second solution comprising a multivalent phosphate crosslinker;mixing the first solution with the second solution, at a pH ranging from about 4 to about 10, to form an adhesive gel; andapplying the adhesive gel to a target location, wherein the small molecule is released from the adhesive gel over a period of time.2. A method of delivering an adhesive to a target location comprising:mixing a polyamine with a multivalent phosphate crosslinker in acidic or basic solution to obtain a mixture;injecting the mixture to a target location; andadjusting the pH of the mixture to ambient pH to form an adhesive gel-like complex in the target location.3. The method of claim 2 , further comprising adjusting the pH to an acidic or basic pH to dissolve the adhesive gel.4. A method of delivering an adhesive to a target location comprising:mixing a polyamine with a multivalent phosphate crosslinker in a solution to obtain a mixture;injecting the mixture to a target location; andadjusting the ionic strength of the solution to form an adhesive gel-like complex in the target location.5. The method of claim 4 , further comprising adjusting the pH to an acidic or basic pH to dissolve the adhesive gel.6. A composition comprising:a non-polysaccharide polymer having two or more amine groups; anda multivalent phosphate crosslinker;the composition comprising an ionically crosslinked network that forms a gel-like coacervate at a pH in the range of from about 4 to about 10.7. The composition of claim 6 , wherein the multivalent phosphate crosslinker is selected from the group consisting of a tetravalent phosphate and a pentavalent phosphate.8. The composition of claim 6 , wherein the ...

System and Methods For Sealing a Channel In Tissue

A system for performing a minimally invasive percutaneous procedure comprises a medical device comprising a hydrogel delivery needle () with a tip and a hydrogel outlet (), an injectable, shear-thinning, self-healing viscoelastic hydrogel that exhibits a storage modulus (G) of at least 600 Pa, and a tan δ (G″/G) from 0.1 to 0.6 in dynamic viscoelasticity measured by a rheometer at 1 Hz and 1% strain rate at 25° C. The system may also comprise a coaxial cannula () having a lumen configured for receipt of the hydrogel delivery needle (), wherein the hydrogel delivery needle comprises an adjustable positioning mechanism () configured to limit the advancement depth of the hydrogel delivery needle through the coaxial cannula to a predetermined depth distal to a distal-most end of the coaxial cannula. 1. A system for sealing a channel in tissue created during a minimally invasive percutaneous procedure , comprising:{'b': 4', '5', '6', '2', '4, 'a medical device comprising a hydrogel delivery needle () with a piercing tip () and a hydrogel outlet (), and a coaxial cannula () having an inner lumen configured for receipt of the hydrogel delivery needle (), and'}an injectable viscoelastic shear-thinning hydrogel.2. A system according to claim 1 , in which the injectable viscoelastic shear-thinning hydrogel exhibits a storage modulus (G′) of at least 400 Pa and a tan δ (G″/G′) from 0.1 to 0.8 in dynamic viscoelasticity measured by a rheometer at 1 Hz and 1% strain rate at 25° C.3. A system according to any preceding claim claim 1 , in which the injectable viscoelastic shear-thinning hydrogel exhibits a compressive modulus of greater than 200 Pa measured at a strain rate of 3 mm/min.4. A system according to any preceding claim claim 1 , in which the shear-thinning viscoelastic hydrogel is configured to exhibit an in-vivo residence time of at least 1 week.5645. A system according to any preceding claim claim 1 , in which the hydrogel outlet () is disposed on a side of the ...

METHOD FOR TREATING ACTIVE BLEEDING USING BIOCOMPATIBLE HEMOSTATIC AND SEALANT COMPOSITIONS

The present specification describes a biocompatible hemostatic composition and a biocompatible tissue sealant, which when used in combination provides a safe and effective method of achieving hemostasis. The biocompatible composition and sealant may be applied either on a surface of the patient's body, or inside the body cavity. The combination may be used to control bleeding from external wounds and internal injuries, as well as to minimize bleeding during surgical procedures. 1. A method of using a combination of a biocompatible hemostatic product and a biocompatible sealant product to treat a bleeding wound within or on a mammal , comprising:applying a first amount of said biocompatible hemostatic product to said bleeding wound; and,applying a second amount of said biocompatible sealant product to the bleeding wound, wherein said first amount and said second amount in combination are sufficient to cause at least one of: hemostasis in said bleeding wound, wound sealing in said wound, reducing exudation of said bleeding wound, promoting tissue healing of said wound, protecting a surface of said wound, and avoiding infection of said wound.2. The method of claim 1 , wherein said biocompatible hemostatic product comprises at least one of a biocompatible hydrophilic hemostatic modified starch claim 1 , cellulose claim 1 , cellulose derivatives claim 1 , chitosan claim 1 , chitosan derivatives claim 1 , alginate and alginate derivatives.3. The method of claim 1 , wherein said biocompatible sealant product comprises at least one of:at least one of a biocompatible modified starch gel, a polysaccharide glue, a fibrin glue, a thrombin glue, and a bioglue; andat least one sugar selected from polysaccharides, oligosaccharides and oligosaccharides, such as Pullulan polysaccharide, maltose, pre-gelatinized starch, Dextran, hydroxypropyl distarch phosphate, sodium carboxymethyl starch, crosslinked carboxymethyl starch, hydroxyethyl starch, oxidized starch, and grafted starch.4. ...

Collecting device for body fluids

A body waste collecting device includes a collecting pouch and an adhesive wafer for attachment to the body. The adhesive wafer includes a backing layer, a first adhesive and a second adhesive. The second adhesive includes a polar plasticising oil or a combination of polar plasticising oils in the content of above 10% (w/w) of the second adhesive, and at least one polar polyethylene copolymer, where the content of the polyethylene copolymer is 10-50% (w/w) of the second adhesive, and the polyethylene copolymer has a melt flow index below 2 g/10 min (190° C./21.1N). 2. The collecting device according to claim 1 , wherein the second adhesive in continuous form exhibiting a moisture vapour transmission rate of at least 100 g/m/day for a 150 μm adhesive sheet when measured according to MVTR Test Method.3. The collecting device according to claim 1 , wherein the polar polyethylene copolymer is selected from the group consisting of ethylene vinyl acetate claim 1 , ethylene vinyl acetate carbon monoxide claim 1 , ethylene butyl acetate claim 1 , ethylene vinyl alcohol claim 1 , ethylene butyl acrylate claim 1 , ethylene butyl acrylate carbon monoxide claim 1 , and combinations thereof.4. The collecting device according to claim 3 , wherein the polar polyethylene copolymer is ethylene vinyl acetate.5. The collecting device according to claim 4 , wherein the ethylene vinyl acetate has a content of at least 40% (w/w) vinyl acetate preferably with 40-80% (w/w) vinyl acetate.6. The collecting device according to claim 1 , wherein the content of the polar polyethylene copolymer is 10-45% (w/w) of the second adhesive preferably 15-30%.7. The collecting device according to claim 1 , wherein the polar polyethylene copolymer has a molecular weight of above 250 claim 1 ,000 g/mol.8. The collecting device according to claim 1 , wherein the polar plasticising oil is selected from the group of liquid rosin derivatives claim 1 , aromatic olefin oligomers claim 1 , vegetable and animal ...

METHODS FOR VAS-OCCLUSIVE CONTRACEPTION AND REVERSAL THEREOF

Disclosed are methods of delivering an agent to the lumen of the vas deferens under guidance of ultrasound imaging. The methods include vas-occlusive contraception in which the vas deferens is non-surgically isolated and an occlusive substance is percutaneously administered into the lumen of the vas deferens under ultrasound. Also disclosed are methods of reversal of vas-occlusive contraception and methods of delivering an agent to the lumen of the vas deferens. Also disclosed are compositions for use in the methods of the invention. 1. A composition comprising:one or more species with a diameter of 0.1 to 1 μm in solvent;wherein the one or more species are capable of forming an implantable network with pores with a diameter of less than or equal to 3 μm;wherein the one or more species and/or the implantable network are capable of being injected into a bodily lumen; andwherein the implantable network has a permanent lifespan in vivo.2. The composition of claim 1 , wherein one or more of the species comprises one or more of natural or synthetic monomers claim 1 , polymers claim 1 , copolymers or block copolymers claim 1 , biocompatible monomers claim 1 , polymers claim 1 , copolymers or block copolymers claim 1 , polystyrene claim 1 , neoprene claim 1 , polyetherether 10 ketone (PEEK) claim 1 , carbon reinforced PEEK claim 1 , polyphenylene claim 1 , polyetherketoneketone (PEKK) claim 1 , polyaryletherketone (PAEK) claim 1 , polyphenylsulphone claim 1 , polysulphone claim 1 , polyurethane claim 1 , polyethylene claim 1 , low-density polyethylene (LDPE) claim 1 , linear low-density polyethylene (LLDPE) claim 1 , high-density polyethylene (HDPE) claim 1 , polypropylene claim 1 , polyetherketoneetherketoneketone (PEKEKK) claim 1 , nylon claim 1 , fluoropolymers claim 1 , polytetrafluoroethylene (PTFE or TEFLON®) claim 1 , TEFLON® TFE (tetrafluoroethylene) claim 1 , polyethylene terephthalate (PET or PETE) claim 1 , TEFLON® FEP (fluorinated ethylene propylene) claim 1 , ...

Gel-forming system for removing urinary calculi and fragments thereof

Primarily described are gel-forming systems, consisting of or comprising a composition (A), comprising one or several cationically crosslinkable polymer(s), and a composition (B), comprising one or several crosslinking agent(s) for crosslinking the cationically crosslinkable polymer(s) for use in a method for removing urinary calculi and/or fragments thereof, more particularly kidney stones and/or fragments thereof, from a region of the urinary tract, more particularly a kidney, that contains urinary calculi and/or fragments thereof, more particularly kidney stones and/or fragments thereof, that are to be removed, with the following steps: (i) providing the compositions (A) and (B), (ii) introducing the compositions (A) and (B) into a region of the urinary tract, more particularly the kidney, that contains urinary calculi and/or fragments thereof, more particularly kidney stones and/or fragments thereof, that are to be removed, under conditions enabling crosslinking of the cationically crosslinkable polymer(s) upon contact of composition (A) with composition (B) so that a crosslinked gel is formed that partly or fully surrounds the urinary calculi and/or fragments thereof, more particularly kidney stones and/or fragments thereof, that are to be removed, (iii) removing the crosslinked gel together with the urinary calculi and/or fragments thereof, more particularly kidney stones and/or fragments thereof, that are surrounded by it from the urinary tract, more particularly the kidney.

Decellularization and recellularization of whole organs

The present invention provides systems and methods for the decellularization and recellularization of tissue segments. In certain instances the invention comprises coating or sealing decellularized tissue segments with a cross-linked alginate hydrogel. The present invention also provides a decellularization kit, which may be used to generate decellularized tissue segments for high throughput studies. Also included are compositions and methods of tissue sealants comprising methacrylated alginate.

MOLECULAR SIEVE/FIBER COMPOSITE MATERIAL AND PREPARATION METHOD THEREOF

The disclosure provides a molecular sieve/fiber composite material comprising molecular sieves and a fiber, the molecular sieves are distributed on the fiber surface and directly contact the fiber surface; the particle diameter D90 of the molecular sieves is 0.01 to 50 μm, the particle size D50 of the molecular sieves is 0.005 to 25 μm; the molecular sieves are distributed uniformly on the fiber surface of the fiber. The disclosure also provides a preparation method for the molecular sieve/fiber composite material and various applications. The molecular sieve/fiber composite material has high strength, elastic recovery ability, and dimensional stability, making the composite material strong and durable. The molecular sieve/fiber composite material has a simple structure, low cost, strong stability, high repeatability of performance, and high practical efficiency, and provides the application in the fields of hemostasis, beauty, deodorization, sterilization, water purification, air purification, and radiation resistance. 1. A molecular sieve/fiber composite material comprising molecular sieves and a fiber , the molecular sieves are distributed on the fiber surface and directly contact the fiber surface;a first particle diameter D90 of the molecular sieves is 0.01 to 50 μm, second particle size D50 of the molecular sieves is 0.005 to 30 μm;the molecular sieves are distributed uniformly on a fiber surface of the fiber; the uniform distribution of the molecular sieves on the fiber surface is detected by the method of: randomly taking n samples of the molecular sieve/fiber composite material at different locations, and analyzing a content of the molecular sieve on the fiber surface, where n is a positive integer greater than or equal to 8, a coefficient of variation of the content of the molecular sieves in the n samples is ≤15%.2. The molecular sieve/fiber composite material of claim 1 , wherein a first surface of the molecular sieve contacted with the fiber is defined ...

BUFFERED ADHESIVE COMPOSITIONS FOR SKIN-ADHERING MEDICAL PRODUCTS

Provided are buffered adhesive compositions comprising a high molecular weight non-neutralized polymeric acid and a high molecular weight partially neutralized polymeric acid and products such as wound dressings and ostomy skin barriers incorporating the compositions. 1. An ostomy skin barrier comprising:a first adhesive that includes a high molecular weight polymeric buffer composition having a high molecular weight polymeric acid present in non-neutralized form and a high molecular weight polymeric acid present in partially neutralized form; anda second adhesive having a composition different from the composition of the first adhesive.2. The ostomy skin barrier of claim 1 , wherein the second adhesive does not contain a high molecular weight polymeric buffer.3. The ostomy skin barrier of claim 1 , wherein the second adhesive has a lower absorptive capacity than the first adhesive.4. The ostomy skin barrier of claim 1 , wherein the second adhesive includes a hydrocolloid.5. The ostomy skin barrier of claim 1 , wherein the non-neutralized high molecular weight polymeric acid is high molecular weight polyacrylic acid and the partially neutralized high molecular weight polymeric acid is partially neutralized high molecular weight polyacrylic acid.6. The ostomy skin barrier of claim 1 , wherein the first adhesive includes 40 wt. % of polyisobutylene claim 1 , 16 wt. % of styrene-isoprene-styrene copolymer claim 1 , 5 wt. % of liquid PIS claim 1 , 4 wt. % of polyethelyene fibers claim 1 , 20 wt. % of cross linked polyacrylic acid claim 1 , and 15 wt. % of cross linked partially neutralized polyacrylic acid.7. The ostomy skin barrier of claim 1 , wherein the second adhesive includes 55.5 wt. % polyisobutylene claim 1 , 14.5 wt. % of styrene-isoprene-styrene copolymer claim 1 , 5 wt. % of polyethylene fibers claim 1 , 8.3 wt. % of pectin claim 1 , and 16.7 wt. % of CMC.8. The ostomy skin barrier of claim 1 , wherein the first adhesive includes 40 wt. % of polyisobutylene ...

Bioadhesive hydrogels

A bioadhesive includes a crosslinked biodegradable hydrogel that includes a plurality of oxidized, acrylated or methacrylated, natural polymer.

OILY COMPOSITIONS

The present invention provides emulsion compositions comprising an continuous oil phase, a discontinuous aqueous phase and a plurality of microparticles. The composition may comprise a pharmaceutical active ingredient located in the oil phase, the particulate phase or the aqueous phase. The emulsion compositions have improved stability and coherence and are useful in the treatment of tumours by embolotherapy. 1. An emulsion composition comprising a continuous phase , a discontinuous phase and a plurality of particles , the discontinuous phase being aqueous and the continuous phase comprising an oil;wherein the particles comprise a polymer to which iodine is covalently bound.2. An emulsion composition comprising a continuous phase , a discontinuous phase and a plurality of particles , the discontinuous phase being aqueous and the continuous phase comprising an oil;wherein the particles are sufficiently hydrophobic such that an emulsion prepared according to example 2 herein, using a lipiodol:aqueous phase ratio of 2:1 and in which the aqueous phase contains no contrast agent, is stable for at least 10 minutes at between 18 and 22° C.3. An emulsion composition comprising a continuous phase , a discontinuous phase and a plurality of particles , the discontinuous phase being aqueous and the continuous phase comprising an oil;wherein the particles, when measured according to Example 4a herein, have a cantilever deflection (measured in volts) of less than that of DC Bead.4. A composition according wherein the particles comprise a polymer to which iodine is covalently bound.5. A composition according to wherein the iodine is bound to an aromatic group claim 1 , which aromatic group is covalently bound to the polymer.6. A composition according to wherein particles comprise a polymer to which iodine is covalently bound claim 1 , and wherein the iodine is present in the particles at a level of at least 30 mg I/ml of packed volume claim 1 , preferably 60 mg iodine per ml PV.7. ...

HYDROGEL INCLUDING SURFACE-TREATED NANOFIBER AND PREPARATION METHOD THEREOF

Provided are a bioadhesive hydrogel including surface-treated nanofibers, a preparation method thereof, and use of thereof. The hydrogel including surface-treated nanofibers provided in the present invention may have excellent bioadhesive strength, thereby being widely applied to a bioadhesive, a scaffold for tissue engineering, a carrier for drug delivery, etc. 1. A bioadhesive hydrogel comprising chitin nanofibers or chitosan nanofibers , wherein the nanofibers are surface-treated nanofibers comprising a dihydroxyphenyl moiety , a trihydroxyphenyl moiety , or tannic acid covalently bound to the surface thereof.3. The bioadhesive hydrogel of claim 2 , wherein the surface treatment material having Chemical Formula 1 is selected from the group consisting of gallic acid claim 2 , pyrogallol claim 2 , catechol claim 2 , DOPA (3 claim 2 ,4-dihydroxyphenylalanine) claim 2 , TOPA (3 claim 2 ,4 claim 2 ,5-trihydroxyphenyllalanine) claim 2 , and pyrogallol.4. The bioadhesive hydrogel of claim 2 , wherein the surface treatment material is comprised in an amount of 0.1 to 30% by weight claim 2 , based on 100% by weight of the nanofibers.5. The bioadhesive hydrogel of claim 1 , wherein the hydrogel has an adhesive strength of 5 to 100 Mpa at a relative humidity of 50% claim 1 , and an adhesive strength of 0.05 Mpa to 10 MPa at a relative humidity of 100%.6. The bioadhesive hydrogel of claim 1 , wherein the hydrogel is bioconjugated with a physiologically active substance.7. The bioadhesive hydrogel of claim 6 , wherein the physiologically active substance is a cell claim 6 , a protein claim 6 , a nucleic acid claim 6 , a sugar claim 6 , an enzyme claim 6 , or a mixture thereof.8. The bioadhesive hydrogel of claim 1 , wherein the hydrogel is formed by bonding between the dihydroxyphenyl moiety claim 1 , the trihydroxyphenyl moiety claim 1 , or the tannic acid bound to the chitin nanofibers or the chitosan nanofibers and metal ions by adding the metal ions.9. The bioadhesive ...

BIOLOGICAL ADHESIVES AND SEALANTS AND METHODS OF USING THE SAME

This invention provides a kit for making an adhesive and/or a sealant which includes: a first composition of alginate and a multivalent cation salt at a concentration ratio (mg/ml) of 30:1 to 1:60, and a second composition of alginate and a buffer, wherein the buffer has a pH value of between 2 to 7. The invention also provides a method for making a sealant or an adhesive, by contacting the first composition and the second composition. 141-. (canceled)42. A kit comprising: a first component and a second component , said first component comprises a crosslinkable polysaccharide and a multivalent cation salt at a concentration ratio (mg/ml) of 30:1 to 1:60 , said second component comprises a crosslinkable polysaccharide and a buffering agent , said buffering agent has a pH value of between 2 to 7 and comprises an acid and its acid addition salt.43. The kit of claim 42 , wherein said crosslinkable polysaccharide is alginate.44. The kit of claim 42 , wherein said crosslinkable polysaccharide and said multivalent cation salt are at a concentration ratio (mg/ml) of 1:1 to 1:4.45. The kit of claim 42 , wherein said multivalent cation salt is selected from:{'sub': 3', '17', '35', '2', '2', '2', '7', '2', '2', '7, 'a calcium salt selected from the group comprising: CaCO, (CHCOO)Ca, CaNaPO, CaPO, or any combination thereof;'}a multivalent cation salt present at a concentration of 20 to 40 mg/ml within said first component; anda particle size between 0.1 microns and 150 microns.46. The kit of claim 42 , wherein said crosslinkable polysaccharide is present at a concentration of 5 to 100 mg/ml within said first component and crosslinkable polysaccharide is present at a concentration of 5 to 100 mg/ml within said second component.47. The kit of claim 42 , wherein said buffering agent has a concentration selected from: a buffering agent having a concentration of between 1 to 2000 mM and a buffering agent having a concentration of 100 to 500 mM.48. The kit of claim 42 , wherein said ...

PANCREATIC FISTULA OCCLUSION

Methods and materials for occluding a pancreatic fistula are described herein. One method for occluding a pancreatic fistula includes administering an effective amount of a self-assembling peptide solution to a pancreatic fistula, where the self-assembling peptide is between about 7 amino acids and 32 amino acids in length and the self-assembling peptide solution forms a hydrogel under physiological conditions, thereby occluding the pancreatic fistula. 1. A method for occluding a pancreatic fistula , the method comprising administering an effective amount of a self-assembling peptide solution to a pancreatic fistula , wherein the self-assembling peptide is between about 7 amino acids and 32 amino acids in length and the self-assembling peptide solution forms a hydrogel under physiological conditions , thereby occluding pancreatic fistula.2. The method of claim 1 , wherein the self-assembling peptide comprises about 12 to about 16 amino acids that alternate between hydrophobic and a hydrophilic amino acids.3. The method of claim 1 , wherein the self-assembling peptide comprises a sequence selected from RADA claim 1 , IEIK claim 1 , TTTT claim 1 , ATAT claim 1 , TVTV claim 1 , ASAS claim 1 , SSSS claim 1 , VVVTTTT claim 1 , and a combination thereof.4. The method of claim 1 , wherein the self-assembling peptide comprises a sequence selected from (RADA) claim 1 , (IEIK)I claim 1 , and (KLDL).5. The method of claim 1 , wherein the self-assembling peptide is about 0.1 to about 10 w/v % of the solution or about 0.1 to about 3.5 w/v % of the solution.6. The method of claim 1 , wherein the self-assembling peptide is about 1 claim 1 , about 2.5 claim 1 , or about 3 w/v % of the solution.7. The method of claim 1 , wherein the effective amount is approximately 0.1 mL per 1 cmto approximately 5 mL per 1 cmof target area.8. The method of claim 1 , wherein the effective amount is approximately 1 mL per 1 cmof target area.9. The method of claim 1 , wherein the hydrogel is formed ...

SKIN COMPATIBLE COMPOSITION

A skin compatible component attachable to mammalian skin. The component is formed as a silicone matrix comprising a polyorganosiloxane derived silicone polymer and moisture control particulate distributed within the polymer network being configured to absorb moisture from the skin. The skin compatible component may be utilised as an ostomy wafer or flange to secure an ostomy appliance to the skin and in particular peri-skin. 1. A skin compatible component attachable to mammalian skin comprising:a silicone polymer network derived from the addition curing of a first part including a vinyl functionalised siloxane polymer and a second part including a silicon hydride containing crosslinker, in the presence of a metal catalyst; anda superabsorbent particulate distributed within the polymer network configured to absorb moisture from the skin;wherein the superabsorbent particulate has an average particle size less than 150 μm.2. The component as claimed in wherein the superabsorbent particulate comprises an average particle size in the range 10 to 40 μm claim 1 , 15 to 35 μm or 20 to 30 μm.3. The component as claimed in wherein the superabsorbent particulate is distributed within the polymer network at a concentration in the range 5 to 45 wt % claim 1 , 10 to 40 wt % claim 1 , 15 to 35 wt % or 20 to 30 wt %.4. The component as claimed in wherein the superabsorbent particulate comprises any one or a combination of the set of:a naturally occurring hydrocolloid;a semi-synthetic hydrocolloid; ora synthetic hydrocolloid.5. The component as claimed in wherein the superabsorbent particulate comprises any one or a combination of:a polysaccharide;a cellulose;hydroxyethylcellulose;carboxymethylcellulose;hydroxypropylcellulose.6. The component as claimed in wherein the superabsorbent particulate comprises any one or a combination of:carboxymethyl β-glucan;cross-linked sodium carboxymethyl cellulose;sodium carboxymethyl cellulose; ormethylcellulose.7. The component as claimed in ...

Hydrogel implants with varying degrees of crosslinking

The present disclosure relates to a hydrogel composition and methods of using the same. The hydrogel composition may include precursors that react with each other upon contact as well as precursors that react upon contact with an initiator. In embodiments, the resulting hydrogels may have varying levels of crosslinking with both denser and less dense regions.

System for sutureless closure of scleral perforations and other ocular tissue discontinuities

The present disclosure describes, among other things, a thereto-responsive hydrogel comprising a PNIPAM copolymer having adhesive properties that are temperature dependent, as well as a device for administering the hydrogel, and methods for making and using the foregoing.

COMPOSITIONS AND METHODS RELATING TO AN OCCLUSIVE POLYMER HYDROGEL

Methods for the synthesis and use of several variations of styrene maleic acid-based polymers and the hydrogel tissue bridges that can be formed from such polymers. Specifically, a method is disclosed for synthesizing a styrene maleic acid-based polymer that can be dissolved in DMSO and injected into the vasa deferentia of male subjects, creating a hydrogel tissue bridge. This hydrogel tissue bridge can occlude the vas deferens, thus forming an effective male contraceptive. Additionally, this male contraceptive can be reversed by injecting the lumen of the vas deferens with a basic buffer solution to dissolve and remove the hydrogel tissue bridge. 1. A hydrogel-forming solution comprising a polymer dissolved in a solvent , wherein the polymer is more than 75% comprised of styrene-alt-maleic acid and the solvent is DMSO.2. The hydrogel forming solution of wherein the ratio of polymer to DMSO is within a weight/weight range from 18% to 40%.3. The hydrogel forming solution of wherein the molecular weight of the polymer is within a range between 100 kDa and 1200 kDa.4. The hydrogel forming solution of wherein a percentage of intermolecular or intramolecular cross-links in the polymer is less than one percent.5. The hydrogel forming solution of wherein a percentage of intermolecular or intramolecular cross-links in the polymer is less than five percent.6. The hydrogel forming solution of wherein a percentage of intermolecular or intramolecular cross-links in the polymer is less than ten percent.7. A method for using a hydrogel-forming solution to create a hydrogel tissue bridge within a space located within a subject claim 1 , the method comprising:providing a hydrogel-forming solution comprising a polymer dissolved in a solvent, wherein the polymer is more than 75% comprised of styrene-alt-maleic acid and the solvent is DMSO;identifying a space within a subject comprising available water and aqueous solutions within the space;utilizing an injecting apparatus to place ...

BIOCOMPATIBLE ADHESIVES AND METHODS OF USE THEREOF

The present invention is directed to a biocompatible adhesive system comprising a) a hydrogel comprising a first polymer network and a second polymer network, wherein the first polymer network comprises covalent crosslinks and the second polymer network comprises ionic crosslinks; b) a high density primary amine polymer; and c) a coupling agent. The present invention also provides methods preparing and using the biocompatible adhesive system. 1. A biocompatible adhesive system comprising:a) a hydrogel comprising a first polymer network and a second polymer network, wherein said first polymer network comprises covalent crosslinks and said second polymer network comprises ionic crosslinks;b) a high density primary amine polymer; andc) a coupling agent.2. The system of claim 1 , wherein the first polymer network is selected from the group consisting of polyacrylamide claim 1 , poly(hydroxyethylmethacrylate) (PHEMA) claim 1 , poly(vinyl alcohol) (PVA) claim 1 , polyethylene glycol (PEG) claim 1 , polyphosphazene claim 1 , collagen claim 1 , gelatin claim 1 , poly(acrylate) claim 1 , poly(methacrylate) claim 1 , poly(methacrylamide) claim 1 , poly(acrylic acid) claim 1 , poly(N-isopropylacrylamide) (PNIPAM) claim 1 , poly(N claim 1 ,N-dimentylacrylamide) claim 1 , poly(allylamine) and copolymers thereof.3. The system of claim 2 , the first polymer network is polyethylene glycol (PEG).4. The system of any one of to claim 2 , wherein the second polymer network is selected from the group consisting of alginate claim 2 , pectate claim 2 , carboxymethyl cellulose claim 2 , oxidized carboxymethyl cellulose claim 2 , hyaluronate claim 2 , chitosan claim 2 , κ-carrageenan claim 2 , ι-carrageenan and λ-carrageenan claim 2 , wherein the alginate claim 2 , carboxymethyl cellulose claim 2 , hyaluronate chitosan claim 2 , κ-carrageenan claim 2 , ι-carrageenan and λ-carrageenan are each optionally oxidized claim 2 , wherein the alginate claim 2 , carboxymethyl cellulose claim 2 , ...

ANTIMICROBIAL HYDROCOLLOID DRESSING CONTAINING SEQUESTERED PEROXIDE AND PREPARATION THEREOF

This disclosure provides a method of preparing a hydrocolloid adhesive that includes the steps of mixing one or more components to produce a continuous phase, heating the continuous phased to a predetermined temperature between about 135° C. to 170° C., adding a stabilizer to the continuous phase, reducing a temperature of the continuous phase to a second predetermined temperature below 99° C., adding a discontinuous phase to the continuous phase at the second predetermined temperature, and mixing the components of the discontinuous phase and the continuous phase to produce a uniform mixture. Further, the hydrocolloid adhesive includes a super absorbent material and 0.05% to 2% by weight of a peroxide. 1. A method of preparing a hydrocolloid adhesive , the method comprising the steps of:mixing one or more components to produce a continuous phase;heating the continuous phase to a predetermined temperature between about 135° C. to 170° C.;adding a stabilizer to the continuous phase;reducing a temperature of the continuous phase to a second predetermined temperature below 99° C.;adding a discontinuous phase to the continuous phase at the second predetermined temperature; andmixing the components of the discontinuous phase and the continuous phase to produce a uniform mixture,wherein the hydrocolloid adhesive comprises a super absorbent material and 0.05% to 2% by weight of a peroxide.2. The method of claim 1 , wherein the step of adding the discontinuous phase to the continuous phase includes adding the peroxide in an amount to produce the hydrocolloid adhesive with 0.05% to 2.0% by weight of the peroxide.3. The method of claim 2 , wherein the step of mixing one or more components to produce a continuous phase comprises mixing a thermoplastic elastomer claim 2 , a polyisobutylene claim 2 , and a liquid rubber.4. The method of claim 3 , the method further including the steps of:adding an oil at a temperature between about 135° C. to about 110° C.;adding a tackifier at a ...

DEXTRAN-BASED POLYMER TISSUE ADHESIVE FOR MEDICAL USE

A tissue adhesive formed by reacting an aminodextran containing primary amine groups with an oxidized dextran containing aldehyde groups is described. The dextran-based polymer tissue adhesive is particularly useful in medical applications where low swell and slow degradation are needed, for example sealing the dura, ophthalmic procedures, tissue repair, antiadhesive applications, drug delivery, and as a plug to seal a fistula or the punctum. 1. A method for applying a coating to an anatomical site on tissue of a living organism comprising:applying to the sitea) at least one dextran that has been derivatized to provide at least one aminodextran that contains primary amine groups, said at least one dextran having a weight-average molecular weight of about 1,000 to about 1,000,000 Daltons, said at least one aminodextran having an amine substitution level of about 5% to about 65%; followed byb) at least one dextran that has been oxidized to provide at least one oxidized dextran containing aldehyde groups, said at least one dextran having a weight-average molecular weight of about 1,000 to about 1,000,000 Daltons, said at least one oxidized dextran having an equivalent weight per aldehyde group of about 65 to about 1500 Daltons; 'or premixing (a) and (b) and applying the resulting mixture to the site.', 'or applying (b) followed by (a) and mixing (a) and (b) on the site;'}2. The method according to wherein the aminodextran is a first aqueous solution or dispersion and the oxidized dextran a second aqueous solution or dispersion.3. The method according to wherein the first aqueous solution or dispersion contains the aminodextran at a concentration of about 5% to about 70% by weight relative to the total weight of the solution or dispersion.4. The method according to wherein the second aqueous solution or dispersion contains the oxidized dextran at a concentration of about 5% to about 50% by weight relative to the total weight of the solution or dispersion.5. The method ...

Elastic Biopolymer and Use as a Tissue Adhesive

The present invention provides an improved tissue adhesive to repair defects in soft tissue. Following ASTM standard tests, crosslinked methacryloyl-substituted gelatin hydrogels of the present invention (GelSEAL) were shown to exhibit adhesive properties, i.e. wound closure strength, shear resistance and burst pressure, that were superior to clinically used fibrin- and poly(ethylene glycol)-based glues. Chronic in vivo experiments in rats proved GelSEAL to effectively seal large lung leakages without additional sutures or staples, presenting improved performance as compared to fibrin and poly(ethylene glycol) glues. Furthermore, subcutaneous implantation in rats revealed high biocompatibility of GelSEAL as evidenced by low inflammatory host response. Advantageously, the tissue adhesives of the present invention are low cost and easy to produce, making them a promising substance to be used as a sealant for fluid leakages in soft tissue, as well as an easily tunable platform to further optimize the adhesive characteristics. 175.-. (canceled)76. A tissue adhesive comprising a light activated methacryloyl-substituted gelatin , a photoinitiator and a pharmaceutically acceptable carrier.77. The tissue adhesive of claim 76 , wherein the methacryloyl-substituted gelatin has a degree of methacryloyl substitution between 50% and 90%.78. The tissue adhesive of claim 76 , wherein the methacryloyl-substituted gelatin is present at a concentration between 10% and 40% (w/v).79. The tissue adhesive of claim 76 , wherein the photoinitiator is selected from the group consisting of: 1-[4-(2-hydroxyethoxy)-phenyl]-2-hydroxy-2-methyl-1-propane-1-one claim 76 , azobisisobutyronitrile claim 76 , benzoyl peroxide claim 76 , di-tert-butyl peroxide claim 76 , 2 claim 76 ,2-dimethoxy-2-phenylacetophenone claim 76 , Eosin Y claim 76 , and any combination thereof.80. The tissue adhesive of claim 76 , further comprising:(i) a hemostatic agent selected from the group consisting of blood ...

OCCLUSIVE IMPLANT COMPOSITIONS

Disclosed are methods of delivering an agent to the lumen of the vas deferens under guidance of ultrasound imaging. The methods include vas-occlusive contraception in which the vas deferens is non-surgically isolated and an occlusive substance is percutaneously administered into the lumen of the vas deferens under ultrasound. Also disclosed are methods of reversal of vas-occlusive contraception and methods of delivering an agent to the lumen of the vas deferens. Also disclosed are compositions for use in the methods of the invention. 1. A composition comprising:one or more species with a diameter of 0.1 to 1 μm in solvent;wherein the one or more species are capable of forming an implantable network with pores with a diameter of less than or equal to 3 μm;wherein the one or more species and/or the implantable network are capable of being injected into a bodily lumen; andwherein the implantable network has a permanent lifespan in vivo.2. The composition of claim 1 , wherein one or more of the species comprises one or more of natural or synthetic monomers claim 1 , polymers claim 1 , copolymers or block copolymers claim 1 , biocompatible monomers claim 1 , polymers claim 1 , copolymers or block copolymers claim 1 , polystyrene claim 1 , neoprene claim 1 , polyetherether 10 ketone (PEEK) claim 1 , carbon reinforced PEEK claim 1 , polyphenylene claim 1 , polyetherketoneketone (PEKK) claim 1 , polyaryletherketone (PAEK) claim 1 , polyphenylsulphone claim 1 , polysulphone claim 1 , polyurethane claim 1 , polyethylene claim 1 , low-density polyethylene (LDPE) claim 1 , linear low-density polyethylene (LLDPE) claim 1 , high-density polyethylene (HDPE) claim 1 , polypropylene claim 1 , polyetherketoneetherketoneketone (PEKEKK) claim 1 , nylon claim 1 , fluoropolymers claim 1 , polytetrafluoroethylene (PTFE or TEFLON®) claim 1 , TEFLON® TFE (tetrafluoroethylene) claim 1 , polyethylene terephthalate (PET or PETE) claim 1 , TEFLON® FEP (fluorinated ethylene propylene) claim 1 , ...

VASCULAR EMBOLIC SYSTEM

Systems and methods of blocking a biological vessel are provided. The systems and methods may comprise introducing to the vessel an amphiphilic peptide. The peptide may comprise at least thirteen amino acids that may alternate between a hydrophobic amino acid and a hydrophilic amino acid. The peptide may form a beta- sheet spontaneously in an aqueous solution in the presence of a cation. 1. A method of blocking one or more targeted biological vessels in a subject comprising:introducing a catheter into a target biological vessel;positioning an end of the catheter in, near, upstream or downstream from a target area of a biological vessel in which at least a partial obstruction of the vessel is desired;administering through the catheter a solution comprising an amphiphilic peptide comprising at least 12 amino acids that alternate between a hydrophobic amino acid and a hydrophilic amino acid in an effective amount and in an effective concentration to form a hydrogel at the target site the hydrogel thereby forming at least a partial blockage of the target biological vessel;removing the catheter from the biological vessel with the at least partial obstruction in place.2. The method of claim 1 , wherein the peptide solution comprises a contrast agent.3. The method of claim 2 , further comprising visualizing a region comprising at least a portion of the targeted biological vessel or vessels.4. The method of claim 3 , wherein visualizing the region comprising at least a portion of the biological vessel comprises visualizing the region during at least one of:identifying the target area of the biological vessel;introducing the catheter;positioning the end of the catheter in the target area;administering the solution;removing the catheter; andvisualizing the biological vessel after removing the catheter.5. The method of claim 4 , wherein visualizing the region comprises imaging using X-ray radiography.6. The method of claim 3 , wherein visualizing the region provides for ...

BUFFERED ADHESIVE COMPOSITIONS FOR SKIN-ADHERING MEDICAL PRODUCTS

Provided are buffered adhesive compositions comprising a high molecular weight non-neutralized polymeric acid and a high molecular weight partially neutralized polymeric acid and products such as wound dressings and ostomy skin barriers incorporating the compositions. 1. An ostomy skin barrier comprising:a first adhesive;a second adhesive, the second adhesive including a hydrocolloid; anda buffer composition.2. The ostomy skin barrier of claim 1 , further comprising:a first barrier surface containing the first adhesive; anda second barrier surface containing the second adhesive.3. The ostomy skin barrier of claim 2 , wherein the first barrier surface is an inner layer formed from the first adhesive and the second barrier surface is a backing layer formed from the second adhesive claim 2 , wherein the backing layer extends over and beyond the inner layer to form an edge portion of the barrier.4. The ostomy skin barrier of claim 2 , wherein the first barrier surface is configured to contact a peristomal area that is immediately adjacent to a wearer's stoma.5. The ostomy skin barrier of claim 1 , wherein the second adhesive has a lower absorptive capacity than the first adhesive.6. The ostomy skin barrier of claim 1 , wherein the buffer composition includes a non-neutralized high molecular weight polymeric acid and a partially neutralized high molecular weight polymeric acid.7. The ostomy skin barrier of claim 6 , wherein the non-neutralized high molecular weight polymeric acid is high molecular weight polyacrylic acid and the partially neutralized high molecular weight polymeric acid is partially neutralized high molecular weight polyacrylic acid.8. The ostomy skin barrier of claim 1 , wherein the buffer composition includes 20 wt. % of cross linked polyacrylic acid and 15 wt. % of cross linked partially neutralized polyacrylic acid.9. The ostomy skin barrier of claim 1 , wherein the second adhesive includes 55.5 wt. % polyisobutylene claim 1 , 14.5 wt. % of styrene- ...

BUFFERED ADHESIVE COMPOSITIONS FOR SKIN-ADHERING MEDICAL PRODUCTS

Provided are buffered adhesive compositions comprising a high molecular weight non-neutralized polymeric acid and a high molecular weight partially neutralized polymeric acid and products such as wound dressings and ostomy skin barriers incorporating the compositions. 1. An ostomy skin barrier comprising:a first barrier surface containing a water insoluble first adhesive;a second barrier surface containing a water insoluble second adhesive that includes a hydrocolloid; anda buffer composition that includes a non-neutralized cross-linked polyacrylic acid and a partially neutralized cross-linked polyacrylic acid.2. The ostomy skin barrier of further comprising an optional ingredient that includes an antioxidant claim 1 , an antibiotic claim 1 , an antimicrobial agent claim 1 , an anti-inflammatory agent claim 1 , a skin protective agent claim 1 , and/or an active ingredient.3. The ostomy skin barrier of claim 1 , wherein the second adhesive has a lower absorptive capacity than the first adhesive.4. The ostomy skin barrier of claim 1 , wherein the first adhesive includes polyisobutylene claim 1 , a styrene-isoprene-styrene copolymer claim 1 , and polyethylene fibers.5. The ostomy skin barrier of claim 1 , wherein the second adhesive includes polyisobutylene claim 1 , a styrene-isoprene-styrene copolymer claim 1 , polyethylene fibers claim 1 , pectin claim 1 , and CMC.6. The ostomy skin barrier of claim 1 , wherein the first barrier surface is an inner layer formed from the first adhesive and the second barrier surface is a backing layer formed from the second adhesive claim 1 , wherein the backing layer extends over and beyond the inner layer to form an edge portion of the barrier.7. The ostomy skin barrier of claim 6 , wherein the first barrier surface is configured to contact a peristomal area that is immediately adjacent to a wearer's stoma.8. The ostomy skin barrier of claim 6 , wherein the first barrier surface includes a release layer.9. A wound dressing ...

HYDROGEL COMPRISING CATECHOL GROUP-COUPLED CHITOSAN OR POLYAMINE AND POLOXAMER COMPRISING THIOL GROUP COUPLED TO END THEREOF, PREPARATION METHOD THEREOF, AND HEMOSTAT USING SAME

The present invention relates to an adhesive hydrogel composition containing catechol group-coupled chitosan and Pluronic comprising a thiol group coupled to the end thereof, and more specifically, to an adhesive composition which is safe in vivo and in vitro, is temperature sensitive, and has an excellent hemostatic effect and thus can be used as a bioadhesive, and a medical adhesive, an adhesion barrier and a surface adsorption inhibitor comprising the same. 1. A hydrogel composition comprising: (i) a catechol group-coupled chitosan or polyamine; and (ii) a polaxamer thiol group-coupled to the end thereof.2. The hydrogel composition of claim 1 , wherein said catechol group-coupled chitosan or polyamine has a molecular weight of 10 claim 1 ,000 Da˜1 claim 1 ,000 claim 1 ,000 Da.3. The hydrogel composition of claim 1 , wherein said catechol group-coupled chitosan or polyamine has a molecular weight of 50 claim 1 ,000 Da˜200 claim 1 ,000 Da.5. The hydrogel composition of claim 1 , wherein said catechol group-coupled polyamine is any one or more selected from the group consisting of ethylene diamine claim 1 , 1 claim 1 ,3-diaminopropane claim 1 , hexamethylenediamine claim 1 , tetraethylmethylenediamine claim 1 , putrescine claim 1 , cadaverine claim 1 , spermidine claim 1 , spermine claim 1 , linear polyethyleneimine claim 1 , branched polyethyleneimine claim 1 , and ε-poly-L-lysine.6. The hydrogel composition of claim 1 , wherein said catechol group-coupled chitosan or polyamine has a 1-20 mole % of catechol group content to the chitosan or polyamine.7. The hydrogel composition of claim 1 , wherein said polaxamer thiol group-coupled to the end thereof has a 50-100 mole % of thiol group content to the polaxamer.8. The hydrogel composition of claim 1 , wherein the hydrogel composition further comprises a therapeutic drug.9. The hydrogel composition of claim 8 , wherein the therapeutic drug is any one or more selected from the group consisting of human growth hormones ...

BIOADHESIVE CHITOSAN GEL FOR CONTROLLING BLEEDING AND FOR PROMOTING HEALING WITH SCAR REDUCTION WITHOUT OBSCURING OR INTERFERING WITH ACCESS TO A SURGICAL FIELD

An aqueous chitosan gel system of novel non-scarring, non-interfering, transparent, stable, solubilized chitosan that controls bleeding is described herein. The aqueous chitosan gel system can comprise water, chitosan, an acid, a plasticizer, a rheology modifying agent, an antioxidant stabilizer, an alcohol, and a multi-valent salt. Additional components of the aqueous chitosan gel system can comprise a bifunctional organic acid, a tnfunctional organic acid, a multi-functional organic acid, a phosphoric acid, a polyphosphoric acid and a salt. 1. An aqueous gel comprising:water in an amount greater than about 80% (w/w);chitosan in an amount of about 2% to about 12% (w/w);an acid component including one or more of a monofunctional organic acid in an amount of about 0.5% to about 7% (w/w), a difunctional or trifunctional organic acid in an amount up to about 5% (w/w), a polyfunctional organic acid in an amount up to about 3% (w/w), an inorganic phosphoric, triphosphoric, or polyphosphoric acid in an amount up to about 3% (w/w);a rheology modifying agent in an amount of about 0.5% to about 5% (w/w);an antioxidant stabilizer in an amount of about 0.1% to about 2.5% (w/w);an alcohol in an amount of about 0.2% to about 10% (w/w); anda multi-valent salt in an amount of about 0.1% to about 0.5% (w/w).2. The aqueous gel of claim 1 , wherein the aqueous gel is at least one of clear and transparent.3. The aqueous gel of claim 1 , wherein the aqueous gel is stable for a period up to three years at about 23° C.4. The aqueous gel of claim 1 , further comprising a plasticizer in an amount up to about 5% (w/w).5. The aqueous gel of claim 1 , wherein the aqueous gel is bioabsorbable and the chitosan has a percent degree of deacetylation between 20% and 40%.6. The aqueous gel of claim 1 , wherein the aqueous gel is removable and the chitosan has a percent degree of deacetylation greater than about 78%.7. The aqueous gel of claim 1 , wherein at least one of: the monofunctional organic ...

ADHESIVE WAFER FOR ATTACHING A WASTE COLLECTING POUCH TO A BODY

An adhesive wafer for attaching a waste collecting pouch to a body includes a backing layer, a skin-facing adhesive layer, and an absorbing adhesive layer. The skin-facing adhesive is liquid impermeable and has a water absorption capacity less than 8 weight % and a moisture vapor transmission rate (MTVR) at least as high as 150 g/m/24 h. The absorbing adhesive layer is disposed between the backing layer and the skin-facing adhesive layer. The absorbing adhesive layer has a water absorption capacity at least as high as 15 weight %. 1. An adhesive wafer for attaching a waste collecting pouch to a body , the adhesive wafer comprising:a backing layer;{'sup': '2', 'a skin-facing adhesive layer, the skin-facing adhesive being liquid impermeable and having a water absorption capacity less than 8 weight % and a moisture vapor transmission rate (MTVR) at least as high as 150 g/m/24 h; and'}an absorbing adhesive layer disposed between the backing layer and the skin-facing adhesive layer, the absorbing adhesive layer having a water absorption capacity at least as high as 15 weight %.2. The adhesive wafer of claim 1 , wherein the absorbing adhesive layer includes absorbent particles.3. The adhesive wafer of claim 2 , wherein the absorbent particles are selected from the group consisting of salts claim 2 , hydrocolloids claim 2 , microcolloids claim 2 , and super absorbers.4. The adhesive wafer of claim 1 , wherein the absorbing adhesive layer has a water absorption capacity between 15% and 48%.5. The adhesive wafer of claim 1 , wherein the MVTR of the skin-facing adhesive layer is between 150 g/m/24 h and 1 claim 1 ,800 g/m/24 h.6. The adhesive wafer of claim 1 , wherein the skin-facing adhesive layer has a water absorption capacity less than 4 weight %.7. The adhesive wafer of claim 1 , wherein the skin-facing adhesive layer includes a polymer that absorbs less than 5 weight % water and has a MVTR at least as high as 100 g/m/24 h.8. The adhesive wafer of claim 7 , wherein the ...

IMAGEABLE POLYMERS

This invention relates to imageable polymers, particularly those comprising poly vinylalcohol and to methods for making them as well as to embolic microspheres comprising the polymers. The microspheres are imageable during embolization procedures and can be loaded with drugs or other therapeutic agents to provide an imageable drug delivery system 137.-. (canceled)38. Hydrogel polymer microspheres wherein the hydrogel polymer comprises: a polyvinyl alcohol (PVA) backbone comprising at least two pendant chains having cross-linkable ethylenically unsaturated functional groups which are cross linked by a vinylic co-monomer;the PVA backbone further comprising 1,3-diol groups acetalised with a radiopaque species which is coupled to the hydrogel polymer through a cyclic acetal group, the radiopaque species comprising one or more covalently bound iodines.39. Hydrogel polymer microspheres according to wherein the pendant chains comprising cross-linkable ethylenically unsaturated functional groups are attached to the 1 claim 38 ,3-diol groups of the PVA backbone via cyclic acetal linkages.40. Hydrogel polymer microspheres according to wherein the vinylic co-monomer is 2-acrylamido-2-methylpropanesulfonic acid.41. Hydrogel polymer microspheres according to wherein the ethylenically unsaturated functional groups are acrylate groups.42. Hydrogel polymer microspheres according to wherein the radiopaque species comprises an iodinated phenyl group.44. Hydrogel polymer microspheres according to wherein claim 43 , Z is (i) a methylene or ethylene group or is (ii) a group —(CH)—O—(CH)— wherein q is 0 claim 43 , 1 or 2 and p is 1 or 2 or is (iii) absent.45. Hydrogel polymer microspheres according to wherein claim 43 , Z is —CHO— claim 43 , —(CH)O— claim 43 , —CHOCH— claim 43 , —(CH)O(CH)— or is absent.46. Hydrogel polymer microspheres according to wherein Hal is 3 or 4 iodines.47. Hydrogel polymer microspheres according to wherein Hal is 2 claim 43 ,3 claim 43 ,5 triiodo claim 43 , 2 ...

APPARATUS AND METHODS FOR SEALING A VASCULAR PUNCTURE

A sealant for sealing a puncture through tissue includes a first section, e.g., formed from freeze-dried hydrogel, and a second section extending from the distal end. The second section may be formed from PEG-precursors including PEG-ester and PEG-amine, e.g., in an equivalent ratio of active group sites of PEG-ester/PEG-amine greater than one-to-one, e.g., such that excess esters may provide faster activation upon contact with physiological fluids and enhance adhesion of the sealant within a puncture. At least some of the precursors remain in an unreactive state until exposed to an aqueous physiological environment, e.g., within a puncture, whereupon the precursors undergo in-situ cross-linking to provide adhesion to tissue adjacent the puncture. For example, the PEG-amine precursors may include the free amine form and the salt form. The free amine form at least partially cross-links with the PEG-ester and the salt form remains in the unreactive state in the sealant before introduction into the puncture. 140-. (canceled)41. A sealant for sealing a puncture extending through tissue , comprising:an elongate first section including proximal and distal ends, wherein the first section is formed from a freeze-dried hydrogel that expands when exposed to physiological fluid within a puncture, anda second section comprising a mass of PEG precursors fused to and extending from the distal end, wherein the mass of PEG precursors comprises PEG-ester precursors and PEG-amine precursors and/or salt forms thereof, and wherein at least some of the PEG-amine precursors are at least partially cross-linked with the PEG-ester precursors, and at least some of the PEG-amine precursors remain in an unreactive state until exposed to an aqueous physiological environment, whereupon the unreactive PEG-amine precursors undergo in-situ cross-linking with the PEG-ester precursors to provide adhesion to tissue adjacent the puncture.42. The sealant of claim 41 , wherein the sealant is disposed ...

Hydrogel Pressure Sealant System

The present invention includes devices, systems, and methods for sealing a defect in body tissue. For example, the present invention includes a device for preventing leakage of air and other gases from the lung during and after lung biopsy. The device delivers a hydrogel composition which forms an air-tight sealant. In certain embodiments, the device simultaneously delivers one or more therapeutic agents, such as lidocaine, to the treatment area. 1. A device for sealing a tissue defect in a body tissue of a subject , wherein the device comprises:a first barrel and a first plunger engaged with the proximal end of the first barrel, thereby forming a first chamber within the first barrel, wherein the first chamber houses a first component of a hydrogel;a second barrel and a second plunger engaged with the proximal end of the second barrel, thereby forming a second chamber within the second barrel chamber, and wherein the second chamber houses a second component of a hydrogel; andat least one port connecting the first chamber and second chamber;wherein the contents of the first chamber and second chamber are temporarily isolated to prevent contact of the first component and second component prior to mixing.2. The device of claim 1 , wherein the port is configured for control by a user to allow communication between the first chamber and second chamber claim 1 , thereby allowing contact of the first component and second component to form a hydrogel solution.3. The device of claim 1 , further comprising at least one outlet positioned on at least one of the first chamber and second chamber.4. The device of claim 1 , wherein the outlet is configured to mate with a delivery instrument claim 1 , selected from the group consisting of a needle and a catheter.5. The device of claim 1 , wherein at least one of the first component and second component comprises one or more therapeutic agents.6. The device of claim 1 , wherein the one or more therapeutic agents comprise one or more ...

SINGLE SOLUTION of Gel-LIKE FIBRIN HEMOSTAT

The present invention trademarked ClotGel© is a fibrin II-based hemostat made of two components that are mixed into a single syringe to be delivered as an adjunct or primary treatment in moderate intraoperative hemorrhage and in trauma. It can be applied topically to the wound either on the skin in a laparatomy or as non-invasive manner in surgical procedures. Its cross-linking technology generates an adhesive stable fibrin clot required for hemostasis. The agent consists of a cross-linked gelatin that is homogenized in a solution of fibrin monomer in acetic acid, which is reconstituted before use from a lyophilized fibrin monomer. When both components are mixed into a syringe they produce a viscous gel-like composition that is polymerized and stabilized when in contact with blood. The attachment properties of the composition, as well as the rapid formation of a fibrin clot, ensures that a strong stable blood clot is formed over a bleeding wound within 2 minutes of application. 1. A composition for the control of bleeding in humans with or without compression comprising:a) lyophilized desAB fibrin monomer (fibrin II)b) acetic acid solution for reconstitution of lyophilized fibrin monomerc) cross-linked gelatin2. The composition as claimed in wherein the acetic acid solution has a pH of 3.4-3.5.3. The composition as claimed in wherein the fibrin monomer in acid solution is mixed 5:1 with dihydrate trehalose USP-NF previous to lyophilization.4. The composition as claimed in wherein the mixture of fibrin monomer with trehalose is lyophilized in particles of 50 μm to 200 μm containing at least 20% fibrin II monomer.5. The composition as claimed in wherein the lyophilized fibrin monomer can be reconstituted in less than two minutes by dissolving the fibrin microparticles it in a solution of acetic acid at pH 3.56. the composition as claimed in wherein the fibrin monomer can be reconstituted in acetic acid solution at a concentration ranging from 20 mg/mL to 40 mg/ml.7. ...

ULTRASOUND DRIVEN MXENE HYDROGEL ELECTRICAL POWER GENERATOR AND METHOD

An electrical power generator includes an M-gel layer that includes MXene and a hydrogel, first and second flexible layers that sandwich the M-gel layer so that the M-gel layer is sealed from an ambient, and a single terminal electrically connected to the M-gel layer. The M-gel layer is configured to transform acoustic energy into electrical energy. 1. An electrical power generator comprising:an M-gel layer that includes MXene and a hydrogel;first and second flexible layers that sandwich the M-gel layer so that the M-gel layer is sealed from an ambient; anda single terminal electrically connected to the M-gel layer,wherein the M-gel layer is configured to transform acoustic energy into electrical energy.2. The electrical power generator of claim 1 , wherein the M-gel layer transforms ultrasound energy.3. The electrical power generator of claim 1 , wherein the first and second flexible layers include a polymer.4. The electrical power generator of claim 1 , wherein a thickness of the M-gel layer is smaller than 1 cm.5. The electrical power generator of claim 1 , wherein a thickness of the M-gel layer is about 1 mm.6. The electrical power generator of claim 5 , wherein a thickness of each of the first and second flexible layers is about 1 mm.7. The electrical power generator of claim 1 , wherein each of the first and second flexible layers are directly in contact with the M-gel layer.8. The electrical power generator of claim 1 , further comprising:first and second positive charged layers,wherein the first positive charged layer is located between the M-gel layer and the first flexible layer, andwherein the second positive charged layer is located between the M-gel layer and the second flexible layer.9. The electrical power generator of claim 8 , wherein the first and second positive charged layers include nylon.10. The electrical power generator of claim 8 , wherein the first and second flexible layers are negative charged layers.11. The electrical power generator of ...

CATECHOL-CONTAINING ADHESIVE HYDROGEL, COMPOSITION FOR PREPARING ADHESIVE HYDROGEL, AND COMPOSITIONS EACH INCLUDING SAID ADHESIVE HYDROGEL

A hydrogel that adheres to the surface of materials is provided by using as constituent elements a water-soluble main chain monomer, crosslinking agent, polymerization initiator, and adhesive monomer having at least a catechol group in a side chain. 121-. (canceled)22. A composition for preparing adhesive hydrogel includinga water-soluble main chain monomer,a crosslinking agent,a polymerization initiator,an adhesive monomer having a catechol group in a side chain, andwater.231. The composition for preparing adhesive hydrogel according to claim wherein the catechol group is derived from DOPA or a derivative thereof.241. The composition for preparing adhesive hydrogel according to claim wherein the water-soluble main chain monomer is a vinyl group-containing monomer.251. The composition for preparing adhesive hydrogel according to claim wherein at least one hydrogen of the catechol group is substituted by a substituent selected from a hydroxyl group , nitro group , carboxy group , and carbonyl group.261. The composition for preparing adhesive hydrogel according to claim that also includes an electrolyte and/or a polar solvent.271. The composition for preparing adhesive hydrogel according to claim wherein the crosslinking agent is a crosslinking agent capable of introducing a three-dimensional crosslinked structure by polymerizable double bonds.281. An adhesive including the composition for preparing adhesive hydrogel according to claim .297. An adhesive containing a hydrogel wherein the adhesive of claim is used asa one-component adhesive where the water-soluble main chain monomer, crosslinking agent, polymerization initiator, and adhesive monomer are included in one componentor a two-component adhesive where the water-soluble main chain monomer, crosslinking agent, and adhesive monomer are included in a first component and the polymerization initiator is included in a second component.307. A medical adhesive wherein the adhesive according to claim is used to adhere ...

TISSUE REPAIR BY STEM CELL RECRUITMENT AND DIFFERENTIATION

Provided herein are compositions and methods for healing cartilage tissue defects or injury by forming fibrochondrocyte cells or fibrochondrocyte-like cells from recruited progenitor cells, such as mesenchymal stem cells. 1. A method of treating a subject having a tissue defect , comprising:(a) providing a scaffold comprising (i) a matrix material, (ii) a chemotactic factor or a profibrogenic factor having a first release duration; and (iii) a chondrogenic factor having a second release duration longer than the first release duration;(b) delivering the scaffold to a tissue defect site;(c) forming a fibrous matrix at the tissue defect site by 6-14 days after scaffold delivery; and(d) forming a fibrocartilaginous matrix comprising fibrochondrocyte cells or fibrochondrocyte-like cells integrated with tissue at the tissue defect site by 4-10 weeks after scaffold delivery.2. The method of claim 1 , wherein providing the scaffold comprises:contacting the scaffold with the chemotactic factor or profibrogenic factor before delivering the scaffold to the tissue defect site; andcontacting the scaffold with the chondrogenic factor before delivering the scaffold to the tissue defect site.3. The method of claim 1 , wherein providing the scaffold comprises:contacting the scaffold with the chemotactic factor or profibrogenic factor after delivering the scaffold to the tissue defect site; andcontacting the scaffold with the chondrogenic factor after delivering the scaffold to the tissue defect site and during or after the release duration of the chemotactic factor or profibrogenic factor.4. The method of claim 1 , wherein providing the scaffold comprises:contacting the scaffold with the chemotactic factor or profibrogenic factor before delivering the scaffold to the tissue defect site; andcontacting the scaffold with the chondrogenic factor after delivering the scaffold to the tissue defect site and during or after the release duration of the chemotactic factor or profibrogenic ...

FIBRIN AND/OR DIALDEHYDE STARCH HYDROLYSATE MATERIALS, AND PREPARATION AND USE THEREOF

Various compositions of matter, methods of making compositions of matter, and methods of using compositions of matter, e.g. for inducing hemostasis, are disclosed. In some embodiments, a starting fibrin material is subjected to controlled hydrolysis, desirably base-catalyzed, to prepare a fibrin hydrolysate material with increased water sorption capacity. Such fibrin hydrolysate materials, alone or combined with one or more additional substances, can be used in the preparation of hemostasis promoting foams, powders or gels. In some embodiments, a starting dialdehyde starch material is subjected to controlled hydrolysis to prepare a dialdehyde starch hydrolysate material. Such dialdehyde starch hydrolysate materials, alone or combined with one or more additional substances, in some cases combined with a fibrin hydrolysate material, can be used in the preparation of hemostasis promoting foams, powders or gels. 1. A method for making a hemostasis promoting material , comprising:subjecting a fibrin-containing starting material to hydrolysis conditions so as to form a fibrin hydrolysate material having an increased sorption capacity, relative to the fibrin starting material, for water at a pH of 7.2. The method according to claim 1 , wherein the hydrolysis conditions comprise contacting the fibrin starting material with a basic liquid medium and/or wherein the fibrin hydrolysate material exhibits a sorption capacity for water at a pH of 7 and a temperature of 20° C. of at least about 10 times its dry weight.3. The method according to claim 1 , wherein the basic liquid medium has a pH in the range of about 10 to 14 and/or wherein the basic liquid medium comprises sodium hydroxide or potassium hydroxide.4. (canceled)5. The method of claim 1 , also comprising lyophilizing the fibrin hydrolysate material.6. (canceled)7. The method of claim 1 , wherein the subjecting is for a period of time of at least about 10 minutes claim 1 , more preferably wherein the period of time is ...

MULTI-COMPONENT ADHESIVE FOR PRODUCING AN ADHESIVE HYDROGEL

The present invention primarily relates to a multicomponent adhesive for producing an adhesive hydrogel, comprising the compound defined below of the formula (I) and one, two, three, four or more further constituents. The invention further relates to the use of said multicomponent adhesive and corresponding methods for gluing two surfaces together. The present invention further relates to a method for producing a corresponding adhesive hydrogel. The invention also relates to a kit comprising a corresponding multicomponent adhesive and one or more further constituents. The invention also relates to articles which comprise a multicomponent adhesive according to the invention or an adhesive hydrogel produced therefrom. 2. The multicomponent adhesive as claimed in claim 1 , further comprising at least one of{'sub': 'B', 'd) a buffer consisting of a buffer acid and a corresponding buffer base, where the pKof the buffer base is not less than 2,'}and{'sub': 'B', 'e) one or more bases with a pK<1.'}3. The multicomponent adhesive as claimed in claim 1 , wherein the first compound of the formula (I) contains at least one cysteine unit.5. The multicomponent adhesive as claimed in claim 1 , wherein at least one of(i) the linker L of the first compound of the formula (I) is an organic molecule unit, the chain members whereof consisting of at least one of (a) exclusively carbon atoms and (b) carbon atoms and hetero atoms,(ii) the linker L′ in the structural unit B-L′-Y (II) is an organic molecule unit, the chain members whereof consisting of at least one of (a) exclusively carbon atoms and (b) carbon atoms and hetero atoms,and(iii) the linker L″ in the structural unit B′-L″-Z′ (III) is an organic molecule unit, the chain members whereof consisting of at least one of (a) exclusively carbon atoms and (b) carbon atoms and hetero atoms.6. The multicomponent adhesive as claimed in claim 1 , wherein the linker L in the first compound of the formula (I) contains at least one structural ...

OSTOMY DEVICE

The present invention relates to an ostomy device for contacting a stoma. The present invention also relates to the use of an ostomy device for contacting a stoma and a kit of parts for preparing an ostomy assembly or system. 1. An ostomy device for contacting a stoma comprising:a laminate structure comprising a substrate layer and an adhesive layer;an aperture formed through the laminate structure and defined by a peripheral wall;wherein the peripheral wall is operable to:expand in the plane of the laminate structure from a pre-expanded state to an expanded state to radially enlarge the aperture to allow insertion of the stoma through the aperture; andcontact the stoma.2. The ostomy device according to claim 1 , wherein once in its expanded state claim 1 , the peripheral wall is further operable to contract from the expanded state towards its pre-expanded state to radially reduce the aperture and contact the stoma with the peripheral wall.3. The ostomy device according to claim 1 , wherein the contact between the peripheral wall and the stoma forms a seal between the peripheral wall and the stoma.4. The ostomy device according to claim 1 , wherein the substrate layer comprises a foam and/or film.5. The ostomy device according to claim 1 , wherein the substrate layer comprises a polymer.6. The ostomy device according to claim 5 , wherein the polymer comprises a polyurethane or polyethylene.7. The ostomy device according to claim 1 , wherein the adhesive layer comprises a hydrocolloid claim 1 , a silicone adhesive claim 1 , an acrylic adhesive claim 1 , a polyurethane adhesive claim 1 , or any combination of two or more thereof; optionally wherein the adhesive layer comprises a hydrocolloid.8. The ostomy device according to claim 7 , wherein the hydrocolloid comprises sodium carboxymethylcellulose claim 7 , polysaccharides and pectin.9. The ostomy device according to claim 1 , wherein the thickness of the substrate layer is from about 0.005 mm to about 0.1 mm.10. The ...

MEDICAL HYDROGEL

A medical hydrogel is formed by in-situ crosslinking an aldehyde-terminated multi-arm star polyethylene glycol and a polyamino compound. The aldehyde group and the multi-arm star polyethylene glycol are linked by a chemical bond such as an ether bond, an amide bond, a urethane bond, an imine bond, or a urea bond. The aldehyde group at the end of the multi-arm polyethylene glycol reacts with the amino group in the polyamino compound to produce Schiff base for crosslinking so that the medical injectable gel is formed. The prepared gel has a short gelling time, a desired gel burst strength, and a good stability in an aqueous solution. 1. A medical hydrogel , formed by in-situ crosslinking an aldehyde-terminated multi-arm star polyethylene glycol and a polyamino compound , wherein the aldehyde group and the multi-arm star polyethylene glycol are linked by a chemical bond such as an ether bond , an amide bond , a urethane bond , an imine bond , or a urea bond.2. The medical hydrogel according to claim 1 , wherein the polyamino compound is selected from one or more of polyethylenimine and polylysine.3. The medical hydrogel according to claim 1 , wherein the aldehyde-terminated multi-arm star polyethylene glycol is a multi-arm polyethylene glycol with not less than 2 arms and a molecular weight of not less than 2000.4. The medical hydrogel according to claim 1 , wherein the aldehyde-terminated multi-arm star polyethylene glycol has 2-8 arms.5. The medical hydrogel according to claim 1 , wherein the aldehyde group is selected from one or more of aromatic aldehydes and alkyl aldehydes.6. Use of the medical hydrogel according to in postoperative tissue closure and anti-leakage claim 1 , anti-tissue adhesion claim 1 , tissue filling claim 1 , tissue repair claim 1 , skin dressing claim 1 , and pharmaceutical preparation.7. A method for preparing the medical hydrogel according to claim 1 , comprising: dissolving the aldehyde-terminated multi-arm star polyethylene glycol in a pH ...

Two-liquid type hemostatic composition and method for manufacturing the same

Provided is a two-liquid type hemostatic composition that may be used adjunctively during a wide range of bleeding events and surgeries, and a method for preparing the same. The two-liquid type hemostatic composition does not contain blood products, comprises a first solution containing chitosan and a second solution containing a glucose or cellulose compound, may be easily applied in a liquid form to a wound or surgical bleeding site of the human body, and may help hemostasis and recovery by immediately forming a hydrogel at the bleeding area.

Antimicrobial hydrocolloid dressing containing sequestered peroxide and preparation thereof

This disclosure provides for an antimicrobial pressure sensitive adhesive composition that includes a sequestered peroxide source and devices that incorporate such a composition.

FIBROUS PROTEINACEOUS NETWORKS AND METHODS OF USE THEREOF

Disclosed herein are engineered bacteria that manufacture biofilms from bacterial amyloid structures. These biofilms and biofilm matrices are capable of generating fibrous proteinaceous networks and being used as 3D-printing inks. 1. An amyloid fusion protein comprising an amyloid protein fused to a fibrous protein.2. The amyloid fusion protein of claim 1 , wherein the amyloid protein is selected from the group consisting of CsgA and fragments thereof claim 1 , A-beta claim 1 , alpha-synuclein claim 1 , TasA claim 1 , and Sup35.3. The amyloid fusion protein of claim 1 , wherein the amyloid protein is CsgA claim 1 , or a fragment thereof.4. The amyloid fusion protein of claim 1 , wherein the fibrous protein is selected from the group consisting of keratin claim 1 , elastin claim 1 , fibrin claim 1 , and collagen claim 1 , or a fragment thereof.5. The amyloid fusion protein of claim 4 , wherein the fibrous protein is fibrin claim 4 , or a fragment thereof.6. The amyloid fusion protein of claim 5 , wherein the fibrous protein comprises an α chain of a fibrinogen.7. (canceled)8. The amyloid fusion protein of claim 5 , wherein the fibrous protein comprises a γ chain of a fibrinogen.9. (canceled)10. The amyloid fusion protein of claim 1 , wherein the fibrous protein is a keratin.11. The amyloid fusion protein of claim 10 , wherein the fibrous protein comprises a K5 keratin.12. (canceled)13. The amyloid fusion protein of claim 10 , wherein the fibrous protein comprises a K14 keratin.14. (canceled)15. A plurality of amyloid fusion proteins comprising a first amyloid fusion protein and a second amyloid fusion protein claim 10 ,wherein the first amyloid fusion protein comprises a first amyloid protein fused to a first fibrous protein; andwherein the second amyloid fusion protein comprises a second amyloid protein fused to a second fibrous protein,wherein the first fibrous protein is aggregated with the second fibrous protein.16. The plurality of amyloid fusion proteins of ...

Adhesive composition

Moisture-curable adhesive compositions, their preparation and use are disclosed herein. The moisture-curable adhesive compositions include one or more reactive polymers, such as reactive silicone polymers, one or more adhesive components, such as a silicone pressure sensitive polymer(s) (PSAs), a cross-linker and a catalyst. Typically, the reactive silicone polymer or polymers are hydroxyl terminated polydimethylsiloxanes (PDMS) having at least two hydroxyl functionalities associated with the polymer(s). 142.-. (canceled)43. A moisture-curable adhesive composition comprising:a reactive component, wherein the reactive component comprises a reactive silicone polymer or a mixture of reactive silicone polymers;{'sub': 3/2', '4/2, 'an adhesive component, wherein the adhesive component comprises a cured polycondensed organopolysiloxane resin that is a reaction product or products of a silanol terminated organopolysiloxane and a silicate organopolysiloxane resin containing at least one RSiOor SiOsiloxyl unit, wherein each R, individually, is H, an alkyl group, aryl group, a reactive functional group or an alkoxy group;'}a cross-linker;and a catalyst.44. The moisture-curable adhesive composition according to claim 43 , wherein the reactive silicone polymer or mixture of reactive silicone polymers comprises a polysiloxane of the formula (I):{'br': None, 'sub': 1', '2', '1', '2', 'n, 'X—RRSi—(O—SiRR)—Y\u2003\u2003(I)'}wherein X and Y are OH;{'sub': 1', '2', '1', '10', '1', '10', '1', '18, 'wherein Rand Rindependently are the same or different and selected form the group consisting of C-Calkyl, C-Calkyl substituted at one or more carbons with one or more halogen atoms, C-Calkyl substituted at one or more carbons with a cyano (—CN) group, phenyl, and phenyl substituted at one or more carbons with a halogen atom or a cyano group; and'}wherein n is a number from 1 to 10,000.45. The moisture-curable adhesive composition according to claim 43 , wherein the reactive silicone polymer ...

Biopolymer System for Tissue Sealing

A tissue sealant for use in surgical and medical procedures for sealing the tissues of a living mammal is provided. The tissue sealant comprises a hydrogel which is formed by gelation of a premix disposed on the tissue to be sealed. The premix comprises alkylated chitosan or a gelatin, and a polybasic carboxylic acid or an oxidized polysaccharide, in an aqueous medium. The premix can also include a dehydrating reagent, a carboxyl activating reagent, or both. A specific use of the tissue sealant is in the repair of the dura mater after brain surgery to prevent leakage of cerebrospinal fluid. The tissue sealant may include a therapeutic or protective agent such as an antibiotic or an anti-inflammatory drug. 1. A tissue sealant for sealing a biological tissue of a living mammal , the sealant comprising a hydrogel , the hydrogel being formed by gelation of a premix , the premix comprising an alkylated chitosan or a gelatin , and a polybasic carboxylic acid or an oxidized polysaccharide , in an aqueous medium.2. (canceled)3. The tissue sealant of wherein the hydrogel is adapted to adhere to biological tissue of a living mammal claim 1 , to adhesively seal the tissue.4. The tissue sealant of wherein the alkylated chitosan comprises poly(oxyalkylene)chitosan claim 1 , the poly(oxyalkylene)chitosan preferably comprising poly(oxyethylene)chitosan.5. The tissue sealant of wherein the alkylated chitosan comprises acrylated chitosan.6. The tissue sealant of wherein the polybasic carboxylic acid comprises an acidic polysaccharide claim 1 , the acidic polysaccharide preferably comprising a hyaluronan or a carboxymethylcellulose.78.-. (canceled)9. The tissue sealant of wherein the oxidized polysaccharide comprises oxidized dextran claim 1 , oxidized starch claim 1 , or oxidized hyaluronan.1011.-. (canceled)12. The tissue sealant of wherein the living mammal is a living human being.1314.-. (canceled)15. The tissue sealant of further comprising a therapeutic or protective agent.1620 ...

Compositions and methods for vas-occlusive contraception

Disclosed are methods of delivering an agent to the lumen of the vas deferens under guidance of ultrasound imaging. The methods include vas-occlusive contraception in which the vas deferens is non-surgically isolated and an occlusive substance is percutaneously administered into the lumen of the vas deferens under ultrasound. Also disclosed are methods of reversal of vas-occlusive contraception and methods of delivering an agent to the lumen of the vas deferens. Also disclosed are compositions for use in the methods of the invention.

GALLIUM-BASED GLASS COMPOSITION

A gallium silica glass composition is described. The glass can be used in variety of biomedical applications 1. A method of treating a vascular structure , said vascular structure having a lumen and a wall , said method comprising:a) introducing a composition into the vascular structure, the composition comprising a first part comprising a polymer matrix and a second part comprising a glass composition having an acid labile tetrahedral structure, the first part and the second part being combinable to form an ionically crosslinked glass polymer matrix composition having an acid labile tetrahedral structure wherein operatively the glass composition cross links into and sets the polymer matrix; andb) allowing the composition to set and form a substantially solid mass within the vascular structure.2. The method of comprising claim 1 , prior to introducing the composition claim 1 , providing an inflatable balloon within the vascular structure and inflating the balloon.3. The method according to wherein the introducing step comprises inserting a catheter into the vascular structure and using the catheter to deliver the composition.4. The method of wherein the matrix comprises an alginate hydrogel.5. The method of wherein the ionically crosslinked glass polymer matrix composition operably forms a biocompatible claim 1 , mechanically stable claim 1 , flexible material claim 1 , providing controlled release of ions within the human body.6. A method of forming an ionically crosslinked glass polymer matrix composition within the human body claim 1 , the method comprising:a. providing a polymer matrix;b. providing a glass composition, the glass composition having an add labile tetrahedral structurec. combining the polymer matrix with the glass composition, the combining effecting a release of at least one component from the glass through an acid reaction so as to cross link into the polymer matrix so as to affect a setting of the glass polymer matrix composition;d. introducing ...

BIOADHESIVE HYDROGELS

A bioadhesive includes a crosslinked biodegradable hydrogel that includes a plurality of oxidized, acrylated or methacrylated, natural polymer. 1. A bioadhesive comprising: a crosslinked biodegradable hydrogel that includes a plurality of oxidized , acrylated or methacrylated , natural polymer macromers crosslinked with a plurality of branched poly(ethylene glycol) macromers.2. The bioadhesive of claim 1 , wherein the oxidized claim 1 , acrylated or methacrylated claim 1 , natural polymer macromers include a plurality of aldehyde groups that are crosslinked with the branched poly(ethylene glycol) macromers.3. The bioadhesive of claim 1 , wherein the oxidized claim 1 , acrylated or methacrylated claim 1 , natural polymer macromers are polysaccharides claim 1 , which are oxidized so that about 1% to about 50% of the saccharide units therein are converted to aldehyde saccharide units.4. The bioadhesive of claim 1 , wherein acrylate or methacrylate groups of the natural polymer macromers are crosslinked so that the hydrogel is dual crosslinked.5. The bioadhesive of claim 1 , the oxidized claim 1 , acrylated or methacrylated claim 1 , natural polymer macromers comprising oxidized claim 1 , acrylated or methacrylated claim 1 , alginates.6. The bioadhesive of claim 1 , wherein the poly(ethylene glycol) macromers are poly(ethylene glycol) amine macromers.7. The bioadhesive of claim 6 , wherein the poly(ethylene glycol) amine macromers are n-arm poly(ethylene glycol) amines claim 6 , where n is an integer greater than 1.8. The bioadhesive of claim 1 , wherein the hydrogel is cytocompatible and claim 1 , upon degradation claim 1 , produces substantially non-toxic products.9. The bioadhesive of claim 1 , wherein the hydrogel is photocrosslinked.10. A bioadhesive comprising: a dual crosslinked biodegradable hydrogel that includes a plurality of oxidized claim 1 , acrylated or methacrylated claim 1 , polysaccharide macromers crosslinked with a plurality of branched poly(ethylene ...

Hydrogel implants with varying degrees of crosslinking

The present disclosure relates to a hydrogel composition and methods of using the same. The hydrogel composition may include precursors that react with each other upon contact as well as precursors that react upon contact with an initiator. In embodiments, the resulting hydrogels may have varying levels of crosslinking with both denser and less dense regions.

Bismuth-thiols as antiseptics for agricultural, industrial and other uses

Compositions and methods, including novel homogeneous microparticulate suspensions, are described for treating natural and artificial surfaces that contain bacterial biofilm, including unexpected synergy or enhancing effects between bismuth-thiol (BT) compounds and certain antibiotics, to provide formulations including antiseptic formulations. Previously unpredicted antibacterial properties and anti-biofilm properties of disclosed BT compounds and BT compound-plus-antibiotic combinations are also described, including preferential efficacies of certain such compositions for treating certain gram-positive bacterial infections, and distinct preferential efficacies of certain such compositions for treating certain gram-negative bacterial infections.

MEDICAL HYDROGEL COMPOSITION, AND MEDICAL HYDROGEL, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF

A medical hydrogel composition, a medical hydrogel, a preparation method therefore and an application thereof, and a medical hydrogel kit. The medical hydrogel composition comprises a first component and a second component; the first component comprises polylysine and polyethylene imine; the second component comprises one or more of 4-arm-polyethylene glycol-succinimidyl glutarate, 4-arm-polyethylene glycol-succinimidyl succinate, and 4-arm-polyethylene glycol-succinimidyl carbonate; the degree of polymerization of the polylysine is 20 or more. The medical hydrogel is formed by reacting the first component with the second component of the medical hydrogel composition. The medical hydrogel kit comprises the medical hydrogel composition and a buffer solution used for dissolving the components of the medical hydrogel composition. The medical hydrogel has a degree of swelling of −10%-50%, and can be applied in narrow parts where cranial, spinal, and peripheral nerves are densely distributed. 1. A medical hydrogel composition , wherein the medical hydrogel composition comprises a first component and a second component , the first component comprises polylysine and polyethylene imine , the second component comprises one or more of 4-arm-polyethylene glycol-succinimidyl glutarate , 4-arm-polyethylene glycol-succinimidyl succinate , and 4-arm-polyethylene glycol-succinimidyl carbonate , and wherein the polylysine has a degree of polymerization of 20 or more , preferably 25 to 35.2. The medical hydrogel composition according to claim 1 , wherein in the first component claim 1 , a mass ratio of the polylysine to the polyethylene imine is 0.1 to 10.3. The medical hydrogel composition according to claim 1 , wherein the polylysine is ε-polylysine and/or poly-L-lysine.4. The medical hydrogel composition according to claim 3 , wherein the weight average molecular weight of the ε-polylysine is 3000 to 5000 Da.5. The medical hydrogel composition according to claim 3 , wherein the ...

BIODEGRADABLE SEALANT AND USE OF A BIODEGRADABLE SEALANT IN MANUFACTURE OF AN AGENT FOR BIOLOGICAL TISSUE ADHESION OR REPAIR

A biodegradable sealant includes: a polyethylene glycol derivative; a photoinitiator; and a solvent, wherein the content of the polyethylene glycol derivative is about 10-75 wt % in the biodegradable sealant. The polyethylene glycol derivative is obtained by a substitution reaction, and in the substitution reaction, the polyethylene glycol is modified with methacrylic anhydride. 1. A biodegradable sealant , comprisinga polyethylene glycol derivative, wherein the polyethylene glycol derivative is obtained through a substitution reaction, and in the substitution reaction, polyethylene glycol is modified with methacrylic anhydride;a photoinitiator; anda solvent,wherein the content of the polyethylene glycol derivative in the biodegradable sealant is about 10-75 wt %.2. The biodegradable sealant as claimed in claim 1 , wherein the molecular weight of the polyethylene glycol used in the substitution reaction is about 1500-35000.3. The biodegradable sealant as claimed in claim 1 , the molecular weight of the polyethylene glycol used in the substitution reaction is about 1500 claim 1 , 8000 or 35000.4. The biodegradable sealant as claimed in claim 1 , wherein the weight ratio of the polyethylene glycol used in the substitution reaction to the methacrylic anhydride used in the substitution reaction is about 1:0.01-10.5. The biodegradable sealant as claimed in claim 1 , wherein the molecular weight of the polyethylene glycol used in the substitution reaction is about 1500 claim 1 , and the weight ratio of the polyethylene glycol used in the substitution reaction to the methacrylic anhydride used in the substitution reaction is about 1:1-10.6. The biodegradable sealant as claimed in claim 1 , wherein the molecular weight of the polyethylene glycol used in the substitution reaction is about 8000 claim 1 , and the weight ratio of the polyethylene glycol used in the substitution reaction to the methacrylic anhydride used in the substitution reaction is about 1:0.05-1.5.7. The ...

BISMUTH-THIOLS AS ANTISEPTICS FOR AGRICULTURAL, INDUSTRIAL AND OTHER USES

Compositions and methods, including novel homogeneous microparticulate suspensions, are described for treating natural and artificial surfaces that contain bacterial biofilm, including unexpected synergy or enhancing effects between bismuth-thiol (BT) compounds and certain antibiotics, to provide formulations including antiseptic formulations. Previously unpredicted antibacterial properties and anti-biofilm properties of disclosed BT compounds and BT compound-plus-antibiotic combinations are also described, including preferential efficacies of certain such compositions for treating certain gram-positive bacterial infections, and distinct preferential efficacies of certain such compositions for treating certain gram-negative bacterial infections. 1. A method for protecting a natural surface of a mammalian tissue or an artificial surface against a bacterial , fungal or viral pathogen , comprising:contacting the natural or artificial surface with an effective amount of a bismuth-thiol (BT) composition under conditions and for a time sufficient for one or more of:(i) prevention of infection of the natural or artificial surface by the bacterial, fungal or viral pathogen,(ii) inhibition of cell viability or cell growth on the natural or artificial surface of substantially all planktonic cells of the bacterial, fungal or viral pathogen,(iii) inhibition of biofilm formation on the natural or artificial surface by the bacterial, fungal or viral pathogen, and(iv) inhibition of biofilm viability or biofilm growth on the natural or artificial surface of substantially all biofilm-form cells of the bacterial, fungal or viral pathogen,wherein the BT composition comprises a substantially monodisperse suspension of microparticles that comprise a BT compound, said microparticles having a volumetric mean diameter of from about 0.4 μm to about 10 μm.220-. (canceled)21. A method for overcoming antibiotic resistance in a plant in or on which an antibiotic-resistant bacterial plant ...

SELF-ASSEMBLING BIOMIMETIC HYDROGELS HAVING BIOADHESIVE PROPERTIES

The disclosure relates to a composition that is liquid at a temperature below the body temperature of a mammal and that solidifies at or above the body temperature of the mammal. The composition includes a thermally-desolubilizable polymer interspersed with a polymeric component of extracellular matrix and an encapsulated form of an amine compound (preferably an aminated component of extracellular matrix) that is de-encapsulated in the body of the mammal. The polymeric component is able to form covalent bonds with amine moieties in the aminated component, in one or more tissues in the body of the mammal, or both. Upon injection of a liquid suspension of these components into the body of the mammal, the thermally-desolubilizable polymer condenses, entrapping the polymeric component. The polymeric component binds covalently with a tissue in the body, and the aminated component end-caps the remaining reactive moieties of the polymeric component, forming a matrix at the site of injection. The disclosure also relates to uses of such compositions for forming a matrix on or within the body of a mammal. The compositions have a variety of uses, such as bioadhesives, as sealants for ruptured tissues, as drug or imaging agent depots, or as mechanical cushions. 1101.-. (canceled)103. The method of claim 102 , wherein said delivering is to a human disc in vivo.104. The method of claim 102 , wherein the TD polymer is selected from the group consisting of poly(ethylene oxides) (PEOs) claim 102 , poly(propylene oxides) (PPOs) claim 102 , copolymers of PEO and poly(lactic acid) (PLA) claim 102 , poly(n-isopropyl acrylamides) (PNIPAAms) claim 102 , mixtures of the foregoing claim 102 , and copolymers of the foregoing.105. The method of claim 102 , wherein the TD polymer is covalently linked with an ECM polymer.106. The method of claim 105 , wherein the ECM polymer is the same polymer as the polymeric component.108. The method of claim 107 , wherein said composition further comprises: ...

HYDROGEL COMPOSITIONS

Fragmented polysaccharide based hydrogel compositions and methods of making and using the same are provided. The subject polysaccharide based hydrogel compositions are prepared by combining a polysaccharide component with a hydrophilic polymer and a cross-linking agent. Also provided are kits and systems for use in preparing the subject compositions. 142-. (canceled)43. A method comprising administering a hydrogel composition to a subject , the hydrogel composition comprising an acetylated polysaccharide , a multifunctional , multi-armed polyethylene glycol polymer and a multifunctional , multi-armed crosslinker of polyethylene glycol , wherein:the acetylated polysaccharide or derivative thereof has a molecular weight of 1000 Dalton to 80,300 Dalton, a degree of deacetylation of 70% to 99%, and at least two nucleophilic groups and is directly covalently bonded to the multifunctional, multi-armed polyethylene glycol polymer and directly covalently bonded to the multifunctional, multi-armed crosslinker of polyethylene glycol;the multifunctional, multi-armed polyethylene glycol polymer has a molecular weight of 5,000 Dalton to 30,000 Dalton, and comprises at least two nucleophilic groups and is directly covalently bonded to the acetylated polysaccharide or derivative thereof and is directly covalently bonded to the multifunctional, multi-armed crosslinker of polyethylene glycol; andthe multifunctional, multi-armed crosslinker of polyethylene glycol has a molecular weight of 5,000 Dalton to 30,000 Dalton, and comprises at least two electrophilic groups and is directly covalently bonded to the acetylated polysaccharide or derivative thereof and is directly covalently bonded to the multifunctional, multi-armed polyethylene glycol polymer,wherein the acetylated polysaccharide or derivative thereof does not act as a cross-linking agent in the hydrogel.44. The method according to claim 43 , wherein administering comprises positioning the hydrogel composition over at least a ...

ELECTROACTIVE BIOADHESIVE COMPOSITIONS

Electrochemically initiated bioadhesive compositions comprising biocompatible polymers containing derivatives of diazonium, arylsulfonium, or diaryliodonium in general, and to their use in tissue fixation, in particular. 1. An electroactive bioadhesive composition comprising an electroactive biocompatible polymer comprising a biocompatible polymer and suitable solvents , surfactants , stabilizers , fillers and/or other additives;wherein the biocompatible polymer comprises a single strand of repeating units and up to 5,000 electroactive groups covalently attached to said strand, wherein precursors of said electroactive groups are selected from the group consisting of a diazonium derivative, an arylsulfonium derivative, a diaryliodonium derivative, and combinations thereof;wherein the biocompatible polymer is selected from the group consisting of poly-L-lactic acid (PLLA), poly(lactide-co-glycolide) (PLGA), poly caprolactone (PCL), polyvinyl pyrrolidone (PVP), polyvinyl alcohol (PVA), collagen, hydroxy propyl cellulose, polyglycerol esters of fatty acids, polysaccharides, and combinations thereof.2. The electroactive bioadhesive composition according to claim 1 , wherein said additives are anti-inflammatory drugs claim 1 , anti-proteases claim 1 , antibiotics claim 1 , or anti-restenosis compounds.3. The electroactive bioadhesive composition according to claim 1 , wherein said composition is in a form of hydrogel.4. The electroactive bioadhesive composition according to claim 1 , wherein said composition is in a form of biocompatible film claim 1 , patch or bondage.5. The electroactive bioadhesive composition according to claim 1 , further comprising conductive particles or polymers of less than 50 micron comprised of gold claim 1 , iron claim 1 , iron oxides claim 1 , platinum claim 1 , magnesium claim 1 , graphene claim 1 , carbon black claim 1 , carbon nanotubes claim 1 , polyacetylene claim 1 , poly(3-alkyl-thiophene) claim 1 , polyaniline claim 1 , ...